



authors declare that no
competing interests exist.
Funding: See page 9
Received: 28 April 2020
Accepted: 23 April 2021
Published: 26 April 2021
Reviewing editor: Edward D
Janus, University of Melbourne,
Australia
Copyright Zhao et al. This
article is distributed under the
terms of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that the
original author and source are
credited.
A Mendelian randomization study of the
role of lipoprotein subfractions in
coronary artery disease
Qingyuan Zhao1*, Jingshu Wang2, Zhen Miao3, Nancy R Zhang4, Sean Hennessy3,
Dylan S Small4, Daniel J Rader3,5
1Statistical Laboratory, University of Cambridge, Cambridge, United Kingdom;
2Department of Statistics, University of Chicago, Chicago, United States; 3Perelman
School of Medicine, University of Pennsylvania, Philadelphia, United States;
4Department of Statistics, University of Pennsylvania, Philadelphia, United States;
5Department of Medicine, University of Pennsylvania, Philadelphia, United States
Abstract Recent genetic data can offer important insights into the roles of lipoprotein
subfractions and particle sizes in preventing coronary artery disease (CAD), as previous
observational studies have often reported conflicting results. We used the LD score regression to
estimate the genetic correlation of 77 subfraction traits with traditional lipid profile and identified
27 traits that may represent distinct genetic mechanisms. We then used Mendelian randomization
(MR) to estimate the causal effect of these traits on the risk of CAD. In univariable MR, the
concentration and content of medium high-density lipoprotein (HDL) particles showed a protective
effect against CAD. The effect was not attenuated in multivariable analyses. Multivariable MR
analyses also found that small HDL particles and smaller mean HDL particle diameter may have a
protective effect. We identified four genetic markers for HDL particle size and CAD. Further
investigations are needed to fully understand the role of HDL particle size.
Introduction
Lipoprotein subfractions have been increasingly studied in epidemiological research and used in clin-
ical practice to predict the risk of cardiovascular diseases (CVD) (Rankin et al., 2014; Mora et al.,
2009; China Kadoorie Biobank Collaborative Group et al., 2018). Several studies have identified
potentially novel subfraction predictors for CVD (Mora et al., 2009; Hoogeveen et al., 2014;
Williams et al., 2014; Ditah et al., 2016; Lawler et al., 2017; Fischer et al., 2014) and demon-
strated that the addition of subfraction measurements can significantly improve the risk prediction
for CVD (Würtz et al., 2012; van Schalkwijk et al., 2014; McGarrah et al., 2016; Rankin et al.,
2014). However, these observational studies often provide conflicting evidence on the precise roles
of the lipoprotein subfractions. For example, while some studies suggested that small, dense low-
density lipoprotein (LDL) particles may be more atherogenic (Lamarche et al., 1997;
Hoogeveen et al., 2014), others found that larger LDL size is associated with higher CVD risk
(Campos et al., 2001; Mora, 2009). Some recent observational studies found that the inverse asso-
ciation of CVD outcomes with smaller high-density lipoprotein (HDL) particles is stronger than the
association with larger HDL particles (Ditah et al., 2016; Kim et al., 2016; McGarrah et al., 2016;
Silbernagel et al., 2017), but other studies reached the opposite conclusion in different cohorts
(Li et al., 2016; Arsenault et al., 2009). Currently, the utility of lipoprotein subfractions or particle
sizes in routine clinical practice remains controversial (Superko, 2009; Mora, 2009; Davidson et al.,
2011; Bays et al., 2016), as there is still a great uncertainty about their causal roles in CVD, largely
due to a lack of intervention data (Bays et al., 2016).
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Mendelian randomization (MR) is an useful causal inference method that avoids many common
pitfalls of observational cohort studies (Smith and Ebrahim, 2003). By using genetic variation as
instrumental variables, MR asks if the genetic predisposition to a higher level of the exposure (in this
case, lipoprotein subfractions) is associated with higher occurrences of the disease outcome
(Didelez and Sheehan, 2007). A positive association suggests a causally protective effect of the
exposure if the genetic variants satisfy the instrumental variable assumptions (Didelez and Sheehan,
2007; Davey Smith and Hemani, 2014). Since MR can provide unbiased causal estimate even when
there are unmeasured confounders, it is generally considered more credible than other non-random-
ized designs and is quickly gaining popularity in epidemiological research (Gidding et al., 2012;
Davies et al., 2018). MR has been used to estimate the effect of several metabolites on CVD, but
most prior studies are limited to just one or a few risk exposures at a time (Emdin et al., 2016;
Ference et al., 2017).
In this study, we will use recent genetic data to investigate the roles of lipid and lipoprotein traits
in the occurrence of coronary artery disease (CAD) and myocardial infarction (MI). In particular, we
are interested in discovering lipoprotein subfractions that may be causal risk factors for CAD and MI
in addition to the traditional lipid profile (LDL cholesterol, HDL cholesterol, and triglycerides levels).
To this end, we will first estimate the genetic correlation of the lipoprotein subfractions and particle
sizes with the tradition risk factors and remove the traits that have a high genetic correlation. We will
then use MR to estimate the causal effects of the selected lipoprotein subfractions and particle sizes
on CAD and MI. Finally, we will explore potential genetic markers for the identified lipoprotein and
subfraction traits.
Materials and methods
GWAS summary datasets and lipoprotein particle measurements
Table 1 describes all GWAS summary datasets used in this study, including two GWAS of the tradi-
tional lipid risk factors (Willer et al., 2013; Hoffmann et al., 2018), two recent GWAS of the human
lipidome (Kettunen et al., 2016; Davis et al., 2017), and three GWAS of CAD or MI (Nikpay et al.,
2015; Nelson et al., 2017; Abbott et al., 2018). In the two GWAS of the lipidome (Kettunen et al.,
2016; Davis et al., 2017), high-throughput nuclear magnetic resonance (NMR) spectroscopy was
used to measure the circulating lipid and lipoprotein traits (Soininen et al., 2009). We investigated
Table 1. Information about the GWAS summary datasets used in this article.
The columns are the phenotypes reported by the GWAS studies, the consortium or name of the first author of the publication,
PubMed ID, population, sample size, other GWAS datasets with other lapping sample, and URLs we used to download the datasets.
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the 82 lipid and lipoprotein traits measured in these studies that are related to very-low-density lipo-
protein (VLDL), LDL, intermediate-density lipoprotein (IDL), and HDL subfractions and particle sizes.
All the subfraction traits are named with three components that are separated by hyphens: the first
component indicates the size (XS, S, M, L, XL, XXL); the second component indicates the fraction
according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third component indicates the mea-
surement (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L for total lipids,
P for particle concentration, PL for phospholipids, TG for triglycerides). For example, M-HDL-P refers
to the concentration of medium HDL particles.
Aside from the concentration and content of lipoprotein subfractions, the two lipidome GWAS
also measured the traditional lipid traits (TG, LDL-C, HDL-C), the average diameter of the fractions
(VLDL-D, LDL-D, HDL-D) and the concentration of apolipoprotein A1 (ApoA1) and apolipoprotein B
(ApoB). A full list of the lipoprotein measurements investigated in this article can be found in
Appendix 1.
Genetic correlation and phenotypic screening
Genetic correlation is a measure of association between the genetic determinants of two pheno-
types. It is conceptually different from epidemiological correlation that can be directly estimated
from cross-sectional data. In this study, we applied the LD-score regression (Bulik-Sullivan et al.,
2015) to the lipidome GWAS (Kettunen et al., 2016; Davis et al., 2017) to estimate the genetic
correlations between the lipoprotein subfractions, particle sizes, and traditional risk factors. We then
removed lipoprotein subfractions and particle sizes that are strongly correlated with the traditional
risk factors, defined as an estimated genetic correlation > 0.8 with TG, LDL-C, HDL-C, ApoB, or
ApoA1 in the GWAS published by Davis et al., 2017. Because these traits are largely co-determined
with the traditional risk factors, they do not represent independent biological mechanisms and may
lead to multicollinearity issues in multivariate MR analyses. Finally, we obtained an independent esti-
mate of the genetic correlations between the selected traits by applying the LD score regression to
the GWAS published by Kettunen et al., 2016. We used Bonferroni’s procedure to correct for multi-
ple testing (familywise error rate at 0.05).
Three-sample Mendelian randomization design
For MR, we employed a three-sample design (Zhao et al., 2019b) in which one GWAS was used to
select independent genetic instruments that are associated with one or several lipoprotein measures.
The other two GWAS were then used to obtain summary associations of the selected SNPs with the
exposure and the outcome, as in a typical two-sample MR design (Pierce and Burgess, 2013;
Hemani et al., 2016). More specifically, the selection GWAS was used to create a set of SNPs that
are in linkage equilibrium with each other in a reference panel (distance >10 megabase pairs,
r
2<0:001). This was done by ordering the SNPs by the p-values of their association with the trait(s)
under investigation and then selecting them greedily using the linkage-disequilibrium (LD) clumping
function in the PLINK software package (Purcell et al., 2007). To avoid winner’s curse, we require
the other two GWAS to have no overlapping sample with the selection GWAS.
As the GWAS published by Davis et al., 2017 has a smaller sample size, we used it to select the
genetic instruments so the larger dataset can be used for statistical estimation. In univariable MR,
associations of the selected SNPs with the exposure trait (a lipoprotein subfraction or a particle size
trait) were obtained from the GWAS published by Kettunen et al., 2016 and the associations with
MI were obtained using summary data from an interim release of UK BioBank (Abbott et al., 2018).
To maximize the statistical power, we used the so-called ‘genome-wide MR’ design. Independent
SNPs are selected by using LD clumping, but we do not truncate the list of SNPs by their p-values.
More details about this design can be found in a previous methodological article (Zhao et al.,
2019b).
To control for potential pleiotropic effects via the traditional risk factors, we performed two multi-
variable MR analyses for each lipoprotein subfraction or particle size under investigation. The first
multivariable MR analysis considers four exposures: TG, LDL-C, HDL-C, and the lipoprotein measure-
ment under investigation. The second multivariable MR analysis replaces LDL-C and HDL-C with
ApoB and ApoA1, in accordance with some recent studies (Richardson et al., 2020). SNPs were
ranked by their minimum p-values with the four exposures and are selected as instruments only if
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they were associated with at least one of the four exposures (p-value  10 4). Both multivariable MR
analyses used the Davis (Davis et al., 2017) and GERA (Hoffmann et al., 2018) datasets for instru-
ment selection, the Kettunen (Kettunen et al., 2016) and GLGC (Willer et al., 2013) datasets for
the associations of the instruments with the exposures, and the CARDIoGRAMplusC4D + UK Bio-
bank (Nelson et al., 2017) dataset for the associations with CAD.
Statistical estimation
For univariable MR, we used the robust adjusted profile score (RAPS) because it is more efficient
and robust than many conventional methods (Zhao et al., 2020; Zhao et al., 2019b). RAPS can con-
sistently estimate the causal effect even when some of the genetic variants violate instrumental varia-
bles assumptions. For multivariable MR, we used an extension to RAPS called GRAPPLE to obtain
the causal effect estimates of multiple exposures (Wang et al., 2020). GRAPPLE also allows the
exposure GWAS to have overlapping sample with the outcome GWAS, while the original RAPS does
not. We assessed the strength of the instruments using the modified Cochran’s Q statistic
(Sanderson et al., 2019). Because many lipoprotein subfraction traits were analyzed simultaneously,
we used the Benjamini-Hochberg procedure to correct for multiple testing (Benjamini and Hoch-
berg, 1995) and the false discovery rate was set to be 0.05. More detail about the statistical meth-
ods can be found in Appendix 3.
Genetic markers for lipoprotein subfractions and CAD
To obtain genetic markers, we selected SNPs that are associated with the lipoprotein measurements
identified in the MR (p-value  5 10 8) and CAD (p-value  0:05) but are not associated with LDL-C
or ApoB (p-value  10 3). To maximize the power of this exploratory analysis, we meta-analyzed the
results of the two lipidome GWAS (Kettunen et al., 2016; Davis et al., 2017) by inverse-variance
weighting. For the associations with LDL-C and CAD, we used the GWAS summary data reported by
the GLGC (Willer et al., 2013) and CARDIoGRAMplusC4D (Nelson et al., 2017) consortia. We used
LD clumping to obtain independent markers (Purcell et al., 2007) and then validate the markers
using tissue-specific gene expression data from the GTEx project.
Sensitivity analysis and replicability
Because we had multiple GWAS summary datasets for the lipoprotein subfractions and CAD/MI
(Table 1), we swapped the roles of the GWAS datasets in the three-sample MR design whenever
permitted by the statistical methods to obtain multiple statistical estimates. These estimates are not
completely independent of the primary results, but they can nonetheless be used to assess replica-
bility. As a sensitivity analysis, We further analyzed univariable MR using inverse-variance weighting
(IVW) (Burgess et al., 2013) and weighted median (Bowden et al., 2016) and compared with the
primary results obtained by RAPS. We also assessed the assumptions made by RAPS using some
diagnostic plots suggested in previous methodological articles (Zhao et al., 2019b).
Results
Genetic correlations and phenotypic screening
We obtained the genetic correlations of the lipoprotein subfractions and particle sizes with the tradi-
tional lipid risk factors: TG, LDL-C, HDL-C, ApoB, and ApoA1 (Table 1). We found that almost all
VLDL subfractions traits (besides those related to very small VLDL subfraction) and the mean VLDL
particle diameter have an estimated genetic correlation with TG very close to 1. Most traits related
to the large and very large HDL subfractions also have a high genetic correlation with HDL-C and
ApoA1.
After removing traits that are strongly correlated with the traditional risk factors, we obtained 27
traits that may involve independent genetic mechanisms. Figure 1 shows the genetic correlation
matrix for these traits and the traditional lipid factors. The selected traits can be divided into two
groups based on whether they are related to VLDL/LDL/IDL particles or HDL particles. Within each
group, most traits were strongly correlated with the others. In the first group, most traits had a posi-
tive genetic correlation with LDL-C and ApoB, while in the second group, most traits had a positive
genetic correlation with HDL-C and ApoA1. Exceptions include LDL-D, which had a negative but
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statistically non-significant genetic correlation with LDL-C and ApoB, and S-HDL-P and S-HDL-L,
which showed no or weak genetic correlation with HDL-C and ApoA1.
Mendelian randomization
Figure 2 shows the estimated causal effect of the selected lipoprotein measurements on MI or CAD
that are statistically significant (false discovery rate = 0.05). The unfiltered results can be found in
Appendix 3, which also contains results of the sensitivity and replicability analyses.
The concentration and lipid content of VLDL, LDL, and IDL subfractions showed harmful and
nearly uniform effects on MI in univariable MR. However, after adjusting for the traditional lipid risk
factors, the effects of these ApoB-related subfractions become close to zero (besides IDL-FC in one
multivariable analysis). The mean diameter of LDL particles (LDL-D) showed a harmful effect on MI in
univariable MR, though the effect was smaller than those of the LDL subfractions in univariable MR.
The estimated effect of LDL-D was attenuated in the multivariable MR analyses.
The concentration and content of medium HDL particles showed protective effects in univariable
and multivariable MR analyses. In particular, adjusting for the traditional lipid risk factors did not
attenuate the effect of traits related to medium HDL. The concentration of and total lipid in small
HDL particles showed protective effects in multivariable MR analyses, though the effect sizes were
smaller than those of the medium HDL traits. The mean diameter of HDL particles (HDL-D) had
almost no effect on MI in the univariable MR analysis, but after adjusting for the traditional lipid risk


























































































































































































































































































































































































































































































































Figure 1. Genetic correlation matrix of the 27 lipoprotein subfraction traits selected in phenotypic screening and five traditional lipid traits. White
asterisk indicates the correlation is statistically significant after Bonferroni correction for multiple comparisons at level 0.05.
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Table 2 reports the estimated effects of M-HDL-P, S-HDL-P, HDL-D, and traditional lipid traits
(TG, LDL-C, HDL-C, ApoB, ApoA1) in the multivariable MR analyses. To better understand the role
of HDL subfractions and particle sizes, we also included in the table the results of the multivariate
MR analyses for the traditional lipid risk factors only. Those baseline analyses suggested that HDL-C/
ApoA1 had a weak, non-significant protective effect on CAD, which is consistent with prior studies
(Holmes et al., 2015; Wang et al., 2020). Adding S-HDL-P to the MR analysis did not substantially
alter the estimated effects of the traditional lipid traits. However, when M-HDL-P or HDL-D was
included in the model, the estimated effects of M-HDL-P and HDL-D changed substantially. In partic-
ular, when M-HDL-P was included in the multivariable MR analyses, HDL-C/ApoA1 showed a harmful



























































































 HDL−C, LDL−C, TG
Figure 2. Results of the Mendelian randomization analyses (false discover rate = 0.05): Estimated odds ratio [95% confidence interval] per standard
deviation increase of the selected lipoprotein measurements on MI or CAD.
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Genetic markers associated with HDL subfractions and CAD
We identified four genetic variants that are associated with S-HDL-P, M-HDL-P, or HDL-D, not asso-
ciated with LDL-C or ApoB, and associated with CAD: rs838880 (SCARB1), rs737337 (DOCK6),
Table 2. Results of some multivariable Mendelian randomization analyses.
Each row in the table corresponds to a multivariable MR analysis with traditional lipid profile and the specified lipoprotein subfraction
or particle size trait. Reported numbers are the point estimates and 95% confidence intervals of the exposure effect.
Trait Effect of TG Effect of LDL-C Effect of HDL-C Effect of subfraction/particle size
None 0.19 [0.09,0.29] 0.38 [0.33,0.44]  0.053 [-0.13,0.03]
M-HDL-P 0.37 [0.22,0.52] 0.39 [0.32,0.45] 0.30 [0.08,0.52]  0.69 [-1.09,–0.3]
S-HDL-P 0.23 [0.12,0.33] 0.45 [0.38,0.52]  0.11 [-0.2,–0.02]  0.33 [-0.52,–0.15]
HDL-D 0.11 [0.00,0.22] 0.42 [0.36,0.49]  0.44 [-0.69,–0.2] 0.33 [0.11,0.56]
Effect of TG Effect of ApoB Effect of ApoA1 Effect of Subfraction/Particle size
None 0.05 [-0.05,0.14] 0.49 [0.38,0.60]  0.095 [-0.21,0.02]
M-HDL-P  0.00 [-0.18,0.17] 0.50 [0.31,0.69] 0.13 [-0.06,0.32]  0.47 [-0.80,–0.15]
S-HDL-P 0.07 [-0.03,0.17] 0.53 [0.41,0.65]  0.13 [-0.25,–0.02]  0.24 [-0.40,–0.08]
HDL-D 0.06 [-0.04,0.15] 0.61 [0.47,0.76]  0.46 [-0.73,–0.19] 0.30 [0.08,0.52]
rs838880−T (SCARB1) rs737337−C (DOCK6) rs2943641−C (IRS1) rs6065904−A (PLTP)






















Figure 3. Genetic markers for HDL size (with risk alleles) and their associations with various lipid traits.
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rs2943641 (IRS1), and rs6065904 (PLTP) (Figure 3). These SNP-cis gene pairs are also supported by
examining expression quantitative trait loci (eQTL) in the tissue-specific GTEx data (Appendix 4).
The first three variants were not associated with S-HDL-P. However, they had uniformly positive asso-
ciations with M-HDL-P, L-HDL-P, XL-HDL-P, HDL-D, ApoA1, and HDL-C, and a negative association
with CAD. The last variant rs6065904 had positive associations with S-HDL-P and M-HDL-P, negative
associations with L-HDL-P, XL-HDL-P, HDL-D, negative but smaller associations with ApoA1 and
HDL-C, and a negative association with CAD.
Sensitivity and replicability analysis
We also investigated the effects of lipoprotein subfractions and particle sizes on MI/CAD using mul-
tiple GWAS datasets, MR designs and statistical methods. The results are provided in Appendix 3
and are generally in agreement with the primary results reported above. The diagnostic plots for
S-HDL-P and M-HDL-P did not suggest evidence of violations of the instrument strength indepen-
dent of direct effect (InSIDE) assumption (Bowden et al., 2015) made by RAPS and GRAPPLE
(Appendix 4).
Discussion
By using recent genetic data and MR, this study examines whether some lipoprotein subfractions
and particle sizes, beyond the traditional lipid risk factors, may play a role in coronary artery disease.
We find that VLDL subfractions have extremely high genetic correlations with blood triglyceride level
and thus offer little extra value. We find some weak evidence that larger LDL particle size may have
a small harmful effect on myocardial infarction and coronary artery disease.
Our main finding is that the size of HDL particles may play an important and previously undiscov-
ered role. Although the concentration and lipid content of small and medium HDL particles appear
to be positively correlated with HDL cholesterol and ApoA1, their genetic correlations are much
smaller than 1, indicating possible independent biological pathway(s). Moreover, the MR analyses
suggested that the small and medium HDL particles may have protective effects on CAD. We also
find that larger HDL mean particle diameter may have a harmful effect on CAD. Finally, we identified
four potential genetic markers for HDL particle size that are independent of LDL cholesterol and
ApoB.
There has been a heated debate on the role of HDL particles in CAD in recent years following the
failure of several trials for CETP inhibitors (Barter et al., 2007; Schwartz et al., 2012; Lincoff et al.,
2017) and recombinant ApoA1 (Nicholls et al., 2018) targeting HDL cholesterol. Observational epi-
demiology studies have long demonstrated strong inverse association between HDL cholesterol and
the risk of CAD or MI (Miller and Miller, 1975; Lewington et al., 2007; Di Angelantonio et al.,
2009), but conflicting evidence has been found in MR studies. In an influential study, Voight and col-
laborators found that the genetic variants associated with HDL cholesterol had varied associations
with CAD and that almost all variants suggesting a protective effect of HDL cholesterol were also
associated with LDL cholesterol or triglycerides (Voight et al., 2012). Other MR studies also found
that the effect of HDL cholesterol on CAD is heterogeneous (Zhao et al., 2019b) or attenuated after
adjusting for LDL cholesterol and triglycerides (Holmes et al., 2017; White et al., 2016).
Notice that the harmful effect of larger HDL particle diameter found in this study relies on includ-
ing HDL-C or ApoA1 in the multivariable MR analysis. Thus, the role of HDL particles in preventing
CAD may be more complicated than, for example, that of LDL cholesterol or ApoB. It is possible
that HDL cholesterol, HDL subfractions, and HDL particle size are all phenotypic markers for some
underlying causal mechanism. A related theory is the HDL function hypothesis (Rader and Hovingh,
2014). Cholesterol efflux capacity, a measure of HDL function, has been documented as superior to
HDL-C in predicting CVD risk (Rohatgi et al., 2014; Saleheen et al., 2015). Recent epidemiologic
studies found that HDL particle size is positively associated with cholesterol efflux capacity in post-
menopausal women (El Khoudary et al., 2016) and in an asymptomatic older cohort
(Mutharasan et al., 2017). However, mechanistic efflux studies showed that small HDL particles
actually mediate more cholesterol efflux (Favari et al., 2009; Du et al., 2015). A likely explanation
of this seeming contradiction is that a high concentration of small HDL particles in the serum may
mark a block in maturation of small HDL particles (Mutharasan et al., 2017). This can also partly
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explain our finding that small HDL traits have a smaller effect than medium HDL traits, as increased
medium HDL might indicate successful maturation of small HDL particles.
Among the reported genetic markers, SCARB1 and PLTP have established relations to HDL
metabolism and CAD. SCARB1 encodes a plasma membrane receptor for HDL and is involved in
hepatic uptake of cholesterol from peripheral tissues. Recently, a rare mutation (P376L) of SCARB1
was reported to raise HDL-C level and increase CAD risk (Zanoni et al., 2016; Samadi et al., 2019).
This is opposite direction to the conventional belief that HDL-C is protective and could be explained
by HDL dysfunction. PLTP encodes the phospholipid transfer protein and mediates the transfer of
phospholipid and cholesterol from LDL and VLDL to HDL. As a result, PLTP plays a complex but piv-
otal role in HDL particle size and composition. Several studies have suggested that high PLTP activity
is a risk factor for CAD (Schlitt et al., 2003; Schlitt et al., 2009; Zhao et al., 2019a).
Our study should be viewed in the context of its limitations, in particular, the inherent limitations
of the summary-data MR design. Any causal inference from non-experimental data makes unverifi-
able assumptions, so does our study. Conventional MR studies assume that the genetic variants are
valid instrumental variables. The statistical methods used by us make less stringent assumptions
about the instrumental variables, but those assumptions could still be violated even though our
model diagnosis does not suggest evidence against the InSIDE assumption. Our study did not adjust
for other risk factors for CAD such as body mass index, blood pressure, and smoking. All the GWAS
datasets used in this study are from the European population, so the same conclusions might not
generalize to other populations. Furthermore, our study used GWAS datasets from heterogeneous
subpopulations, which may also introduce bias (Zhao et al., 2019c). We also did not use more than
one subfraction traits as exposures in multivariable MR because of their high genetic correlations.
Alternative statistical methods could be used to select the best causal risk factor from high-through-
put experiments (Zuber et al., 2019). Finally, as pointed out by revieweres, triglycerides has a
greater intra-individual biological variability than HDL particle size. It is likely that triglycerides and
HDL size represent a gene/environment interaction with a very large environmental component. Fur-
ther investigations are needed to fully understand this mechanism.
Recently, a NMR spectroscopy method has been developed to estimate HDL cholesterol efflux
capacity from serum (Kuusisto et al., 2019). That method can form the basis of a genetic analysis of
HDL cholesterol efflux capacity and may complement the results here. We believe more laboratorial
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Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikäinen LP, Pirinen
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Appendix 1
Lipid and lipoprotein traits
Two published GWAS of the human lipidome [Kettunen2016, Davis2017] measured lipoprotein sub-
fractions and particle sizes using NMR spectroscopy. We investigated the 82 lipid and lipoprotein
traits measured in these studies that are related to very-low-density lipoprotein (VLDL), LDL, and
HDL subfractions and particle sizes. All the subfraction traits are named using three components
separated by hyphen: the first indicates the size (XS, S, M, L, XL, XXL); the second indicates the cate-
gory according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third indicates the measure-
ment (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L for total lipids, P
for particle concentration, PL for phospholipids, TG for triglycerides). A full list of lipid and lipopro-
tein traits used in our study can be found in Appendix 1—table 1 below.
Appendix 1—table 1. All 82 traits included in this study and whether they are measured in the
Kettunen and Davis GWAS (NA means not available).
Trait Description Kettunen Davis
VLDL traits and total triglycerides
TG Total triglycerides
VLDL-D VLDL diameter
XS-VLDL-L Total lipids in very small VLDL NA
XS-VLDL-P Concentration of very small VLDL particles
XS-VLDL-PL Phospholipids in very small VLDL
XS-VLDL-TG Triglycerides in very small VLDL
S-VLDL-C Total cholesterol in small VLDL
S-VLDL-FC Free cholesterol in small VLDL
S-VLDL-L Total lipids in small VLDL NA
S-VLDL-P Concentration of small VLDL particles
S-VLDL-PL Phospholipids in small VLDL
S-VLDL-TG Triglycerides in small VLDL
M-VLDL-C Total cholesterol in medium VLDL
M-VLDL-CE Cholesterol esters in medium VLDL
M-VLDL-FC Free cholesterol in medium VLDL
M-VLDL-L Total lipids in medium VLDL NA
M-VLDL-P Concentration of medium VLDL particles
M-VLDL-PL Phospholipids in medium VLDL
M-VLDL-TG Triglycerides in medium VLDL
L-VLDL-C Total cholesterol in large VLDL
L-VLDL-CE Cholesterol esters in large VLDL
L-VLDL-FC Free cholesterol in large VLDL
L-VLDL-L Total lipids in large VLDL NA
L-VLDL-P Concentration of large VLDL particles
L-VLDL-PL Phospholipids in large VLDL
L-VLDL-TG Triglycerides in large VLDL
XL-VLDL-L Total lipids in very large VLDL NA
XL-VLDL-P Concentration of very large VLDL particles
XL-VLDL-PL Phospholipids in very large VLDL
XL-VLDL-TG Triglycerides in very large VLDL
Continued on next page
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Appendix 1—table 1 continued
Trait Description Kettunen Davis
XXL-VLDL-L Total lipids in chylomicrons and extremely very large VLDL NA
XXL-VLDL-P Concentration of chylomicrons and extremely very large VLDL particles
XXL-VLDL-PL Phospholipids in chylomicrons and extremely very large
XXL-VLDL-TG Triglycerides in chylomicrons and extremely very large
LDL and IDL traits
LDL-C Total cholesterol in LDL
ApoB Apolipoprotein B
LDL-D LDL diameter
S-LDL-C Total cholesterol in small LDL
S-LDL-L Total lipids in small LDL NA
S-LDL-P Phospholipids in small LDL
M-LDL-C Total cholesterol in medium LDL
M-LDL-CE Cholesterol esters in medium LDL
M-LDL-L Total lipids in medium LDL NA
M-LDL-P Concentration of medium LDL particles
M-LDL-PL Phospholipids in medium LDL
L-LDL-C Total cholesterol in large LDL
L-LDL-CE Cholesterol esters in large LDL
L-LDL-FC Free cholesterol in large LDL
L-LDL-L Total lipids in large LDL NA
L-LDL-P Concentration of large LDL particles
L-LDL-PL Phospholipids in large LDL
IDL-C Total cholesterol in IDL
IDL-FC Free cholesterol in IDL
IDL-L Total lipids in IDL NA
IDL-P Concentration of IDL particles
IDL-PL Phospholipids in IDL
IDL-TG Triglycerides in IDL
HDL traits
HDL-C Total cholesterol in HDL
ApoA1 Apolipoprotein A1
HDL-D HDL diameter
S-HDL-L Total lipids in small HDL NA
S-HDL-P Concentration of small HDL particles
S-HDL-TG Triglycerides in small HDL
M-HDL-C Total cholesterol in medium HDL
M-HDL-CE Cholesterol esters in medium HDL
M-HDL-FC Free cholesterol in medium HDL
M-HDL-L Total lipids in medium HDL NA
M-HDL-P Concentration of medium HDL particles
M-HDL-PL Phospholipids in medium HDL
L-HDL-C Total cholesterol in large HDL
Continued on next page
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Appendix 1—table 1 continued
Trait Description Kettunen Davis
L-HDL-CE Cholesterol esters in large HDL
L-HDL-FC Free cholesterol in large HDL
L-HDL-L Total lipids in large HDL NA
L-HDL-P Concentration of large HDL particles
L-HDL-PL Phospholipids in large HDL
XL-HDL-C Total cholesterol in very large HDL
XL-HDL-CE Cholesterol esters in very large HDL
XL-HDL-FC Free cholesterol in very large HDL
XL-HDL-L Total lipids in very large HDL NA
XL-HDL-P Concentration of very large HDL particles
XL-HDL-PL Phospholipids in very large HDL
XL-HDL-TG Triglycerides in very large HDL
Zhao et al. eLife 2021;10:e58361. DOI: https://doi.org/10.7554/eLife.58361 17 of 47
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Appendix 2
Genetic correlations
We estimated the genetic correlation between lipoprotein subfractions, particle sizes, and traditional
lipid risk factors using the LD score regression (Li et al., 2016). Appendix 2—figure 1–3 show the
estimated genetic correlation matrix between selected traits using different datasets. Below the fig-
ures, Appendix 2—table 1 shows the estimated genetic correlations of the lipoprotein subbfractions
with the traditional lipid risk factors using the Davis GWAS. The results in Appendix 2—table 1

























































































































































































































































































































































































































































































Appendix 2—figure 1. Genetic correlations computed using the Davis et al., 2017 GWAS summary
dataset.
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Appendix 2—figure 2. Genetic correlations computed using the Kettunen et al., 2016 GWAS sum-
mary dataset.
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Appendix 2—figure 3. Genetic correlations computed by meta-analyzing the results in Appen-
dix 2—figures 1 and 2.
Appendix 2—table 1. Estimated genetic correlation (standard error) of the lipoprotein subfractions
with the traditional lipid risk factors using the Davis GWAS.
Bolded estimates are above 0.8 and the corresponding traits were removed in phenotypic screening.
Trait ApoA1 ApoB HDL-C LDL-C TG
S-HDL-L 0.31 (0.28) 0.34 (0.25) 0.13 (0.26) 0.27 (0.3) 0.2 (0.22)
S-HDL-P 0.36 (0.24) 0.27 (0.22)  0.01 (0.22) 0.1 (0.31) 0.48 (0.17)
S-HDL-TG  0.13 (0.25) 0.77 (0.13)  0.66 (0.15) 0.13 (0.28) 1.03 (0.07)
M-HDL-C 0.65 (0.14)  0.18 (0.2) 0.81 (0.09)  0.09 (0.25)  0.34 (0.17)
M-HDL-CE 0.68 (0.14)  0.23 (0.21) 0.57 (0.12)  0.24 (0.24)  0.32 (0.18)
M-HDL-FC 0.67 (0.12)  0.08 (0.21) 0.83 (0.08) 0.04 (0.24)  0.28 (0.18)
M-HDL-L 0.71 (0.15) 0.02 (0.27) 0.52 (0.17)  0.03 (0.29)  0.19 (0.25)
M-HDL-P 0.75 (0.12) 0.15 (0.23) 0.46 (0.14) 0.08 (0.26) 0 (0.19)
M-HDL-PL 0.69 (0.13) 0.04 (0.22) 0.65 (0.11) 0.02 (0.25)  0.04 (0.19)
L-HDL-C 0.76 (0.11)  0.42 (0.13) 0.95 (0.02)  0.1 (0.18)  0.62 (0.09)
L-HDL-CE 0.82 (0.1)  0.4 (0.12) 0.93 (0.04)  0.16 (0.17)  0.62 (0.09)
L-HDL-FC 0.66 (0.12)  0.46 (0.13) 0.92 (0.03)  0.13 (0.18)  0.7 (0.08)
L-HDL-L 0.81 (0.11)  0.29 (0.15) 0.74 (0.07)  0.15 (0.18)  0.56 (0.12)
L-HDL-P 0.79 (0.09)  0.35 (0.13) 0.82 (0.05)  0.12 (0.16)  0.61 (0.09)
Continued on next page
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Appendix 2—table 1 continued
Trait ApoA1 ApoB HDL-C LDL-C TG
L-HDL-PL 0.77 (0.09)  0.34 (0.13) 0.79 (0.05)  0.12 (0.17)  0.61 (0.09)
XL-HDL-C 0.75 (0.16)  0.25 (0.19) 0.9 (0.1) 0.4 (0.27)  0.63 (0.13)
XL-HDL-CE 0.82 (0.16)  0.17 (0.19) 0.82 (0.09) 0.41 (0.27)  0.54 (0.12)
XL-HDL-FC 0.72 (0.14)  0.37 (0.18) 0.94 (0.08) 0.17 (0.23)  0.71 (0.11)
XL-HDL-L 0.93 (0.16)  0.08 (0.25) 0.68 (0.14) 0.1 (0.27)  0.35 (0.2)
XL-HDL-P 0.81 (0.13)  0.32 (0.16) 0.86 (0.08) 0.17 (0.21)  0.69 (0.11)
XL-HDL-PL 0.76 (0.12)  0.41 (0.15) 0.83 (0.07)  0.09 (0.18)  0.7 (0.09)
XL-HDL-TG 0.72 (0.13) 0.49 (0.17) 0.33 (0.13) 0.13 (0.26) 0.3 (0.15)
HDL-D 0.7 (0.11)  0.36 (0.13) 0.8 (0.06)  0.08 (0.17)  0.64 (0.09)
IDL-C 0.38 (0.21) 0.58 (0.19) 0.07 (0.19) 0.8 (0.14) 0.39 (0.17)
IDL-FC 0.23 (0.2) 0.78 (0.12)  0.05 (0.17) 0.61 (0.19) 0.44 (0.15)
IDL-L 0.38 (0.23) 0.65 (0.18) 0.05 (0.2) 0.64 (0.2) 0.47 (0.17)
IDL-P 0.31 (0.2) 0.66 (0.14)  0.04 (0.17) 0.82 (0.13) 0.49 (0.14)
IDL-PL 0.25 (0.23) 0.83 (0.1)  0.12 (0.19) 0.7 (0.19) 0.64 (0.15)
IDL-TG 0.22 (0.18) 0.82 (0.08)  0.2 (0.13) 0.56 (0.15) 0.67 (0.08)
S-LDL-C 0.11 (0.28) 0.66 (0.18)  0.16 (0.22) 0.44 (0.34) 0.58 (0.14)
S-LDL-L 0.26 (0.23) 0.66 (0.17)  0.06 (0.21) 0.62 (0.21) 0.58 (0.13)
S-LDL-P 0.34 (0.2) 0.68 (0.15)  0.02 (0.19) 0.63 (0.18) 0.58 (0.13)
M-LDL-C 0.15 (0.26) 0.63 (0.18) 0.22 (0.22) 0.87 (0.08) 0.13 (0.23)
M-LDL-CE 0.3 (0.23) 0.61 (0.2) 0.05 (0.21) 0.65 (0.2) 0.45 (0.16)
M-LDL-L 0.29 (0.22) 0.63 (0.18) 0.01 (0.21) 0.66 (0.19) 0.5 (0.15)
M-LDL-P 0.29 (0.23) 0.63 (0.18)  0.01 (0.21) 0.65 (0.21) 0.51 (0.15)
M-LDL-PL 0.2 (0.24) 0.69 (0.16) 0.11 (0.2) 0.89 (0.06) 0.18 (0.22)
L-LDL-C 0.25 (0.24) 0.58 (0.21) 0.25 (0.22) 0.68 (0.19) 0.23 (0.21)
L-LDL-CE 0.3 (0.23) 0.58 (0.22) 0.05 (0.21) 0.65 (0.21) 0.41 (0.17)
L-LDL-FC 0.31 (0.24) 0.57 (0.22) 0.33 (0.23) 0.7 (0.18) 0.13 (0.23)
L-LDL-L 0.31 (0.23) 0.61 (0.2) 0.04 (0.21) 0.65 (0.21) 0.44 (0.17)
L-LDL-P 0.31 (0.23) 0.63 (0.19) 0.02 (0.21) 0.65 (0.21) 0.47 (0.16)
L-LDL-PL 0.27 (0.25) 0.61 (0.2) 0.24 (0.22) 0.67 (0.2) 0.27 (0.2)
LDL-D  0.33 (0.25)  0.22 (0.23)  0.15 (0.21)  0.15 (0.29)  0.37 (0.16)
XS-VLDL-L 0.25 (0.23) 0.8 (0.08)  0.2 (0.17) 0.61 (0.14) 0.73 (0.09)
XS-VLDL-P 0.17 (0.18) 0.83 (0.07)  0.26 (0.13) 0.57 (0.13) 0.71 (0.07)
XS-VLDL-PL 0.21 (0.19) 0.78 (0.09)  0.15 (0.15) 0.74 (0.14) 0.57 (0.11)
XS-VLDL-TG 0.06 (0.18) 0.83 (0.08)  0.37 (0.11) 0.56 (0.13) 0.85 (0.04)
S-VLDL-FC  0.08 (0.2) 0.94 (0.05)  0.49 (0.12) 0.59 (0.12) 0.92 (0.03)
S-VLDL-L  0.12 (0.24) 0.7 (0.08)  0.46 (0.15) 0.5 (0.14) 0.8 (0.05)
S-VLDL-P  0.09 (0.19) 0.78 (0.07)  0.48 (0.11) 0.5 (0.14) 0.95 (0.02)
S-VLDL-PL  0.03 (0.2) 0.82 (0.08)  0.43 (0.12) 0.44 (0.17) 0.92 (0.03)
S-VLDL-TG  0.1 (0.2) 0.9 (0.08)  0.49 (0.11) 0.49 (0.15) 0.98 (0.01)
S-VLDL-C 0.01 (0.2) 0.9 (0.06)  0.39 (0.13) 0.61 (0.15) 0.89 (0.05)
M-VLDL-C  0.01 (0.2) 0.8 (0.09)  0.47 (0.12) 0.41 (0.18) 0.95 (0.02)
M-VLDL-CE 0.01 (0.19) 0.78 (0.08)  0.43 (0.12) 0.5 (0.15) 0.9 (0.03)
Continued on next page
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Appendix 2—table 1 continued
Trait ApoA1 ApoB HDL-C LDL-C TG
M-VLDL-FC 0 (0.21) 0.83 (0.09)  0.48 (0.12) 0.4 (0.18) 0.97 (0.01)
M-VLDL-L  0.1 (0.24) 0.66 (0.11)  0.48 (0.15) 0.4 (0.18) 0.8 (0.05)
M-VLDL-P  0.06 (0.19) 0.78 (0.1)  0.46 (0.12) 0.43 (0.16) 0.98 (0.02)
M-VLDL-PL 0.03 (0.21) 0.85 (0.09)  0.48 (0.12) 0.4 (0.18) 0.98 (0.01)
M-VLDL-TG  0.02 (0.21) 0.82 (0.11)  0.5 (0.13) 0.33 (0.19) 0.98 (0.02)
L-VLDL-C  0.05 (0.2) 0.83 (0.12)  0.55 (0.12) 0.36 (0.19) 1 (0.02)
L-VLDL-CE 0 (0.19) 0.78 (0.12)  0.44 (0.12) 0.43 (0.19) 0.93 (0.03)
L-VLDL-FC  0.03 (0.2) 0.84 (0.12)  0.53 (0.13) 0.36 (0.19) 1 (0.02)
L-VLDL-L  0.06 (0.24) 0.66 (0.14)  0.47 (0.16) 0.36 (0.2) 0.86 (0.05)
L-VLDL-P  0.02 (0.21) 0.72 (0.12)  0.44 (0.13) 0.33 (0.18) 0.98 (0.02)
L-VLDL-PL 0.01 (0.21) 0.86 (0.12)  0.53 (0.13) 0.3 (0.2) 1.04 (0.03)
L-VLDL-TG  0.06 (0.21) 0.78 (0.12)  0.54 (0.13) 0.26 (0.19) 1 (0.02)
XL-VLDL-L  0.08 (0.24) 0.7 (0.15)  0.52 (0.16) 0.43 (0.2) 0.85 (0.05)
XL-VLDL-P  0.06 (0.2) 0.76 (0.12)  0.48 (0.13) 0.44 (0.18) 0.95 (0.03)
XL-VLDL-PL  0.09 (0.23) 0.82 (0.13)  0.62 (0.15) 0.32 (0.21) 1.06 (0.04)
XL-VLDL-TG  0.14 (0.21) 0.86 (0.13)  0.65 (0.13) 0.34 (0.19) 1.03 (0.04)
XXL-VLDL-L  0.07 (0.25) 0.65 (0.16)  0.5 (0.17) 0.38 (0.22) 0.83 (0.06)
XXL-VLDL-P 0.17 (0.2) 0.72 (0.15)  0.3 (0.15) 0.39 (0.21) 0.86 (0.07)
XXL-VLDL-PL  0.3 (0.24) 0.66 (0.17)  0.8 (0.16) 0.22 (0.21) 1.06 (0.06)
XXL-VLDL-TG  0.21 (0.25) 0.64 (0.16)  0.7 (0.15) 0.22 (0.22) 1.08 (0.05)
VLDL-D  0.22 (0.2) 0.55 (0.14)  0.53 (0.12) 0.12 (0.19) 0.86 (0.04)
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Appendix 3
Mendelian randomization
We implemented several Mendelian randomization (MR) designs and statistical methods to estimate
the causal effect of lipoprotein subfractions and particles sizes on coronary artery disease. In general,
we adopted the three-sample summary data MR design described in Zhao et al., 2019b,
Wang et al., 2020 and we swapped the roles of the GWAS datasets whenever permitted by the sta-
tistical methods. More specifically, the statistical methods we used for univariable MR (RAPS, IVW,
weighted median) require that the GWAS datasets for obtaining instruments, SNP effects on the
exposure, and SNP effects on the outcome must have no overlapping sample. The multivariable MR
method we used (GRAPPLE) allows the exposure and outcome GWAS to be dependent and esti-
mates the proportion of overlapping sample. However, GRAPPLE still requires that the selection
GWAS uses an non-overlapping sample.
The MR designs we implemented in this study are summarized in Appendix 3—table 1. We con-
sidered two ways of instrument selection for univariable MR. In ‘traditional selection’, the traditional
lipid traits were used to select the instruments for the corresponding subfraction traits. That is,
HDL-C was used to select SNPs for HDL subfractions and particle size, LDL-C for IDL and LDL sub-
fractions and particle size, and TG for VLDL subfractions and particle size. This tends to select more
instruments because the GWAS for traditional lipid traits had a larger sample size. In ‘subfraction
selection’, the instrumental SNPs were selected for each lipoprotein subfraction and particle size
using the same or closest trait in the selection GWAS. For example, if the exposure under investiga-
tion is S-HDL-L but it is not measured in the Davis GWAS (if it is used for selection), S-HDL-P is used
instead for instrument selection.
For multivariable MR, we considered two models with different sets of exposures: TG, LDL-C,
HDL-C, and the subfraction/particle size under investigation; TG, ApoB, ApoA1, and the subfrac-
tion/particle size under investigation. SNPs were selected as potential instruments if they were asso-
ciated (p-value  10 4) with at least one of the four exposures. LD clumping was then used to obtain
independent instruments, as described in Materials and Methods.
We briefly comment on the statistical methods used in univariable MR. All the three methods we
used—RAPS, IVW, weighted median—require that the exposure GWAS and outcome GWAS have
non-overlapping samples. RAPS and weighted median can provide consistent estimate of the causal
effect even when some of the genetic variants are not valid instruments, provided that the direct
effects of the genetic variants are independent of the strength of their associations with the expo-
sure. The last condition is called the Instrument Strength Independent of Direct Effect (InSIDE)
assumption in the MR literature [bowden2015mendelian]. RAPS is also robust to idiosyncratically
large direct effect (Bowden et al., 2015). Because IVW and weighted median can be severely biased
by weak instruments (Zhao et al., 2020), we only used them with the set of SNPs that have genome-
wide significant association (p-value  5 10 8) with the exposure. In comparison, RAPS does not
suffer from weak instrument bias and we used it with all the SNPs obtained by LD clumping without
any p-value threshold.
Below, Appendix 3—figure 1 shows the MR results for the 27 lipoprotein measurements selected
in phenotypic screening. Estimates that are statistically significant at a false discovery rate of 0.05
are shown in Figure 2 of the main paper. Appendix 3—table 2 shows the estimated effect of all the
lipoprotein subfractions and particle sizes on myocardial infarction or coronary artery disease in vari-
ous MR designs. Full results of the multivariable MR analyses, including the estimated effects of the
traditional lipid risk factors, can be found in Appendix 3—tables 5 and 6. The results of the univari-
able MR analyses using IVW and weighted median estimators can be found in Appendix 3—tables
3 and 4.
Appendix 3—table 1. Three-sample Mendelian randomization designs.
MR design Selection Exposure Outcome Reported in
Continued on next page
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Appendix 3—table 1 continued




GERA Davis CARDIoGRAMplusC4D Appendix 3—table 2–4
GERA Davis UK Biobank Appendix 3—table 2–4
GERA Kettunen UK Biobank Appendix 3—table 2–4




Davis Kettunen UK Biobank Figure 2; Appendix 3—figure 1 and
Appendix 3—table 2–4








Figure 2, Table 2; Appendix 3—figure 1














































































































































































 HDL−C, LDL−C, TG
Appendix 3—figure 1. Mendelian randomization results for the 27 lipoprotein measurements
selected in phenotypic screening.
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In the tables below, Red indicates p-value is significant (at level 0.05) after Bonferroni correction
for all the results in the corresponding table and blue indicates p-value  0.05.
Appendix 3—table 2. Mendelian randomization results using all selected SNPs (univariable MR
using RAPS and multivariable MR using GRAPPLE).
Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis

































-0.588 (0.094) -0.32 (0.112)
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0.3 (0.112) -1.081 (0.282) -0.673 (0.217)
Continued on next page
Zhao et al. eLife 2021;10:e58361. DOI: https://doi.org/10.7554/eLife.58361 25 of 47
Research article Genetics and Genomics Medicine
Appendix 3—table 2 continued
Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
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NA -0.069 (0.191) NaN
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Appendix 3—table 2 continued
Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
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Appendix 3—table 2 continued
Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
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0.147 (0.074) 0.165 (0.086)
Univariable MR results
Appendix 3—table 3. Mendelian randomization results using genome-wide significant SNPs and
inverse variance weighted (IVW) estimator.
Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
Continued on next page
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Appendix 3—table 3 continued
Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
VLDL traits
TG 0.184 (0.051) 0.278 (0.076) NA 0.309 (0.074) NA 0.207 (0.064)
VLDL-D 0.044 (0.06) 0.052 (0.09) 0.038 (0.102) 0.118 (0.091) -0.083 (0.16) -0.083 (0.138)
XS-VLDL-L NA NA 0.353 (0.08) NA 0.372 (0.083) NA
XS-VLDL-P 0.162 (0.04) 0.256 (0.059) 0.352 (0.081) 0.273 (0.063) 0.374 (0.084) 0.373 (0.095)
XS-VLDL-PL 0.165 (0.046) 0.262 (0.069) 0.37 (0.088) 0.27 (0.075) 0.443 (0.048) 0.401 (0.07)
XS-VLDL-TG 0.179 (0.041) 0.277 (0.061) 0.362 (0.082) 0.288 (0.062) 0.335 (0.076) 0.314 (0.08)
S-VLDL-C 0.237 (0.053) 0.343 (0.08) NA 0.339 (0.083) NA 0.443 (0.116)
S-VLDL-FC 0.21 (0.05) 0.307 (0.076) 0.344 (0.098) 0.314 (0.076) 0.262 (0.122) 0.397 (0.116)
S-VLDL-L NA NA 0.318 (0.095) NA 0.27 (0.106) NA
S-VLDL-P 0.188 (0.049) 0.274 (0.074) 0.311 (0.093) 0.29 (0.072) 0.266 (0.103) 0.331 (0.142)
S-VLDL-PL 0.198 (0.048) 0.291 (0.072) 0.342 (0.091) 0.3 (0.072) 0.281 (0.089) 0.331 (0.125)
S-VLDL-TG 0.174 (0.051) 0.255 (0.076) 0.296 (0.094) 0.28 (0.073) 0.261 (0.102) 0.262 (0.093)
M-VLDL-C 0.188 (0.053) 0.265 (0.08) 0.305 (0.096) 0.287 (0.077) 0.361 (0.078) 0.32 (0.134)
M-VLDL-CE 0.203 (0.051) 0.285 (0.077) 0.32 (0.098) 0.295 (0.076) 0.264 (0.094) 0.291 (0.125)
M-VLDL-FC 0.165 (0.056) 0.233 (0.084) 0.292 (0.098) 0.27 (0.08) 0.3 (0.084) 0.303 (0.104)
M-VLDL-L NA NA 0.265 (0.104) NA 0.357 (0.096) NA
M-VLDL-P 0.153 (0.056) 0.214 (0.085) 0.276 (0.104) 0.258 (0.081) 0.322 (0.092) 0.268 (0.074)
M-VLDL-PL 0.163 (0.054) 0.23 (0.082) 0.296 (0.097) 0.266 (0.078) 0.302 (0.084) 0.289 (0.095)
M-VLDL-TG 0.14 (0.058) 0.196 (0.087) 0.268 (0.107) 0.247 (0.083) 0.327 (0.093) 0.245 (0.091)
L-VLDL-C 0.177 (0.06) 0.24 (0.091) 0.288 (0.106) 0.286 (0.089) 0.108 (0.223) 0.31 (0.084)
L-VLDL-CE 0.178 (0.057) 0.245 (0.087) 0.262 (0.105) 0.279 (0.086) 0.182 (0.187) 0.299 (0.077)
L-VLDL-FC 0.176 (0.063) 0.242 (0.094) 0.295 (0.108) 0.298 (0.091) 0.321 (0.101) 0.314 (0.082)
L-VLDL-L NA NA 0.291 (0.119) NA 0.125 (0.232) NA
L-VLDL-P 0.164 (0.062) 0.227 (0.093) 0.269 (0.108) 0.275 (0.09) 0.332 (0.127) 0.247 (0.076)
L-VLDL-PL 0.173 (0.061) 0.23 (0.092) 0.308 (0.115) 0.284 (0.088) 0.32 (0.127) 0.302 (0.079)
L-VLDL-TG 0.149 (0.063) 0.202 (0.095) 0.268 (0.118) 0.267 (0.092) 0.33 (0.131) 0.302 (0.08)
XL-VLDL-L NA NA 0.263 (0.123) NA 0.365 (0.286) NA
XL-VLDL-P 0.149 (0.063) 0.206 (0.095) 0.247 (0.122) 0.268 (0.096) 0.346 (0.28) 0.245 (0.077)
XL-VLDL-PL 0.176 (0.067) 0.243 (0.101) 0.292 (0.119) 0.323 (0.101) 0.333 (0.265) 0.344 (0.133)
XL-VLDL-TG 0.151 (0.066) 0.205 (0.1) 0.241 (0.12) 0.282 (0.1) 0.323 (0.272) 0.249 (0.081)
XXL-VLDL-L NA NA 0.356 (0.127) NA -0.165 (0.425) NA
XXL-VLDL-P 0.228 (0.067) 0.35 (0.099) 0.372 (0.119) 0.376 (0.098) -0.12 (0.389) 0.006 (0.153)
XXL-VLDL-PL 0.211 (0.07) 0.31 (0.105) 0.275 (0.125) 0.399 (0.107) -0.145 (0.395) 0.071 (0.191)
XXL-VLDL-TG 0.221 (0.067) 0.3 (0.102) 0.292 (0.126) 0.415 (0.104) 0.09 (0.36) 0.349 (0.303)
IDL/LDL traits
LDL-C 0.427 (0.049) 0.431 (0.054) 0.409 (0.077) 0.409 (0.054) 0.416 (0.099) 0.422 (0.063)
ApoB 0.506 (0.058) 0.525 (0.065) 0.474 (0.093) 0.473 (0.064) 0.636 (0.092) 0.569 (0.071)
LDL-D 0.217 (0.151) 0.423 (0.161) 1.121 (0.178) 0.271 (0.143) 0.309 (0.126) 0.211 (0.081)
S-LDL-C 0.481 (0.056) 0.467 (0.063) 0.445 (0.087) 0.438 (0.063) 0.44 (0.128) 0.436 (0.076)
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Appendix 3—table 3 continued
Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
S-LDL-L NA NA 0.44 (0.09) NA 0.456 (0.132) NA
S-LDL-P 0.501 (0.059) 0.494 (0.068) 0.449 (0.093) 0.472 (0.067) 0.49 (0.139) 0.588 (0.097)
M-LDL-C 0.475 (0.057) 0.457 (0.064) 0.426 (0.08) 0.427 (0.064) 0.418 (0.111) 0.436 (0.087)
M-LDL-CE 0.485 (0.058) 0.47 (0.065) 0.432 (0.078) 0.436 (0.064) 0.43 (0.107) 0.444 (0.085)
M-LDL-L NA NA 0.43 (0.08) NA 0.43 (0.11) NA
M-LDL-P 0.479 (0.057) 0.465 (0.064) 0.437 (0.081) 0.44 (0.064) 0.413 (0.122) 0.439 (0.093)
M-LDL-PL 0.5 (0.063) 0.49 (0.071) 0.437 (0.087) 0.464 (0.07) 0.443 (0.132) 0.497 (0.099)
L-LDL-C 0.449 (0.055) 0.436 (0.061) 0.432 (0.076) 0.411 (0.061) 0.409 (0.106) 0.417 (0.076)
L-LDL-CE 0.464 (0.056) 0.451 (0.062) 0.426 (0.075) 0.422 (0.062) 0.416 (0.102) 0.433 (0.077)
L-LDL-FC 0.425 (0.054) 0.411 (0.059) 0.424 (0.074) 0.393 (0.059) 0.387 (0.105) 0.394 (0.078)
L-LDL-L NA NA 0.427 (0.074) NA 0.407 (0.103) NA
L-LDL-P 0.448 (0.054) 0.442 (0.06) 0.435 (0.075) 0.421 (0.059) 0.413 (0.104) 0.424 (0.075)
L-LDL-PL 0.444 (0.056) 0.438 (0.061) 0.441 (0.078) 0.423 (0.061) 0.42 (0.109) 0.429 (0.076)
IDL-C 0.447 (0.055) 0.455 (0.059) 0.451 (0.075) 0.433 (0.06) 0.439 (0.085) 0.422 (0.07)
IDL-FC 0.429 (0.055) 0.439 (0.059) 0.468 (0.075) 0.414 (0.059) 0.431 (0.081) 0.402 (0.074)
IDL-L NA NA 0.467 (0.075) NA 0.445 (0.085) NA
IDL-P 0.443 (0.055) 0.467 (0.06) 0.48 (0.077) 0.45 (0.059) 0.446 (0.088) 0.426 (0.071)
IDL-PL 0.429 (0.055) 0.443 (0.059) 0.473 (0.078) 0.427 (0.059) 0.435 (0.092) 0.407 (0.069)
IDL-TG 0.461 (0.07) 0.518 (0.076) 0.625 (0.098) 0.494 (0.073) 0.342 (0.085) 0.34 (0.123)
HDL traits
HDL-C -0.085 (0.044) -0.156 (0.057) -0.146 (0.085) -0.195 (0.06) -0.082 (0.159) -0.015 (0.109)
ApoA1 -0.072 (0.054) -0.155 (0.071) -0.036 (0.09) -0.194 (0.074) 0.001 (0.192) 0.066 (0.158)
HDL-D -0.027 (0.042) -0.071 (0.058) -0.052 (0.073) -0.092 (0.063) 0.073 (0.098) 0.074 (0.074)
S-HDL-L NA NA -0.064 (0.148) NA -0.033 (0.092) NA
S-HDL-P -0.117 (0.087) -0.172 (0.116) -0.13 (0.146) -0.298 (0.117) -0.033 (0.09) -0.115 (0.174)
S-HDL-TG 0.224 (0.063) 0.317 (0.082) 0.496 (0.107) 0.344 (0.085) 0.334 (0.096) 0.286 (0.17)
M-HDL-C -0.214 (0.062) -0.327 (0.078) -0.48 (0.111) -0.39 (0.079) -0.423 (0.175) -0.39 (0.159)
M-HDL-CE -0.227 (0.062) -0.338 (0.077) -0.497 (0.111) -0.4 (0.078) -0.435 (0.194) -0.341 (0.238)
M-HDL-FC -0.158 (0.065) -0.272 (0.084) -0.341 (0.117) -0.337 (0.085) -0.288 (0.218) -0.278 (0.144)
M-HDL-L NA NA -0.436 (0.125) NA -0.514 (0.223) NA
M-HDL-P -0.172 (0.066) -0.292 (0.087) -0.414 (0.132) -0.361 (0.089) -0.386 (0.307) -0.18 (0.118)
M-HDL-PL -0.161 (0.064) -0.275 (0.085) -0.38 (0.126) -0.345 (0.087) -0.419 (0.301) -0.2 (0.099)
L-HDL-C -0.047 (0.044) -0.097 (0.059) -0.124 (0.08) -0.133 (0.063) 0.022 (0.106) 0.021 (0.105)
L-HDL-CE -0.049 (0.044) -0.098 (0.059) -0.12 (0.079) -0.137 (0.063) 0.023 (0.112) 0.004 (0.106)
L-HDL-FC -0.044 (0.046) -0.094 (0.062) -0.106 (0.082) -0.127 (0.067) 0.038 (0.103) 0.017 (0.109)
L-HDL-L NA NA -0.106 (0.077) NA 0.034 (0.102) NA
L-HDL-P -0.045 (0.043) -0.097 (0.058) -0.102 (0.077) -0.125 (0.063) 0.009 (0.111) 0.025 (0.11)
L-HDL-PL -0.054 (0.044) -0.11 (0.06) -0.115 (0.079) -0.14 (0.064) 0.006 (0.115) 0.016 (0.115)
XL-HDL-C 0.03 (0.06) -0.012 (0.084) 0.014 (0.099) -0.05 (0.088) -0.015 (0.165) 0.161 (0.101)
XL-HDL-CE 0.03 (0.059) -0.009 (0.081) 0.025 (0.098) -0.042 (0.086) -0.001 (0.166) 0.221 (0.107)
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Appendix 3—table 3 continued
Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
XL-HDL-FC -0.003 (0.056) -0.05 (0.076) -0.001 (0.089) -0.077 (0.081) 0.072 (0.11) 0.057 (0.092)
XL-HDL-L NA NA 0.001 (0.085) NA -0.009 (0.138) NA
XL-HDL-P 0.015 (0.049) -0.021 (0.067) 0.013 (0.088) -0.042 (0.071) 0.103 (0.1) 0.135 (0.093)
XL-HDL-PL 0 (0.047) -0.037 (0.065) -0.026 (0.079) -0.055 (0.069) 0.081 (0.088) 0.071 (0.069)
XL-HDL-TG 0.086 (0.041) 0.103 (0.059) 0.14 (0.075) 0.13 (0.063) 0.165 (0.043) 0.126 (0.051)
Appendix 3—table 4. Mendelian randomization results using genome-wide significant SNPs and the
weighted median estimator.
Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
VLDL traits
TG 0.042 (0.055) 0.191 (0.072) NA 0.228 (0.069) NA 0.195 (0.077)
VLDL-D -0.098 (0.052) 0.039 (0.095) 0.057 (0.11) 0.058 (0.093) -0.107 (0.099) -0.052 (0.115)
XS-VLDL-L NA NA 0.312 (0.076) NA 0.393 (0.078) NA
XS-VLDL-P 0.101 (0.037) 0.23 (0.052) 0.303 (0.079) 0.229 (0.052) 0.409 (0.08) 0.253 (0.059)
XS-VLDL-PL 0.096 (0.039) 0.242 (0.059) 0.352 (0.087) 0.228 (0.06) 0.422 (0.065) 0.319 (0.062)
XS-VLDL-TG 0.125 (0.041) 0.266 (0.057) 0.287 (0.079) 0.221 (0.056) 0.361 (0.084) 0.306 (0.069)
S-VLDL-C 0.187 (0.059) 0.232 (0.075) NA 0.256 (0.074) NA 0.303 (0.094)
S-VLDL-FC 0.152 (0.057) 0.207 (0.069) 0.289 (0.093) 0.227 (0.069) 0.316 (0.109) 0.279 (0.077)
S-VLDL-L NA NA 0.282 (0.083) NA 0.306 (0.099) NA
S-VLDL-P 0.131 (0.057) 0.202 (0.069) 0.275 (0.085) 0.221 (0.062) 0.291 (0.093) 0.226 (0.078)
S-VLDL-PL 0.137 (0.053) 0.205 (0.067) 0.283 (0.083) 0.218 (0.062) 0.305 (0.092) 0.263 (0.075)
S-VLDL-TG 0.112 (0.057) 0.204 (0.067) 0.216 (0.088) 0.229 (0.064) 0.267 (0.099) 0.244 (0.073)
M-VLDL-C 0.12 (0.058) 0.2 (0.07) 0.255 (0.088) 0.213 (0.066) 0.303 (0.099) 0.224 (0.081)
M-VLDL-CE 0.144 (0.054) 0.207 (0.071) 0.262 (0.087) 0.207 (0.068) 0.301 (0.098) 0.209 (0.072)
M-VLDL-FC 0.081 (0.058) 0.188 (0.074) 0.221 (0.087) 0.218 (0.068) 0.272 (0.102) 0.231 (0.08)
M-VLDL-L NA NA 0.227 (0.095) NA 0.275 (0.109) NA
M-VLDL-P 0.047 (0.06) 0.191 (0.072) 0.221 (0.096) 0.226 (0.069) 0.31 (0.104) 0.257 (0.079)
M-VLDL-PL 0.103 (0.056) 0.197 (0.071) 0.228 (0.089) 0.217 (0.064) 0.29 (0.104) 0.231 (0.078)
M-VLDL-TG -0.005 (0.06) 0.199 (0.075) 0.224 (0.089) 0.222 (0.068) 0.318 (0.113) 0.233 (0.085)
L-VLDL-C 0.109 (0.068) 0.2 (0.078) 0.237 (0.093) 0.231 (0.075) 0.242 (0.122) 0.262 (0.088)
L-VLDL-CE 0.147 (0.063) 0.211 (0.079) 0.249 (0.09) 0.253 (0.073) 0.281 (0.11) 0.286 (0.081)
L-VLDL-FC 0.045 (0.065) 0.199 (0.085) 0.225 (0.093) 0.224 (0.077) 0.252 (0.125) 0.228 (0.089)
L-VLDL-L NA NA 0.243 (0.102) NA 0.261 (0.122) NA
L-VLDL-P 0.041 (0.064) 0.209 (0.082) 0.224 (0.092) 0.21 (0.079) 0.289 (0.122) 0.223 (0.086)
L-VLDL-PL 0.08 (0.063) 0.201 (0.08) 0.244 (0.101) 0.224 (0.077) 0.278 (0.123) 0.247 (0.092)
L-VLDL-TG -0.008 (0.061) 0.215 (0.084) 0.225 (0.103) 0.161 (0.077) 0.286 (0.13) 0.277 (0.093)
XL-VLDL-L NA NA 0.262 (0.111) NA NA NA
Continued on next page
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Appendix 3—table 4 continued
Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
XL-VLDL-P -0.026 (0.063) 0.207 (0.091) 0.289 (0.102) 0.192 (0.088) NA 0.209 (0.101)
XL-VLDL-PL -0.006 (0.067) 0.197 (0.094) 0.253 (0.094) 0.213 (0.088) NA 0.24 (0.101)
XL-VLDL-TG -0.026 (0.064) 0.214 (0.092) 0.229 (0.102) 0.191 (0.088) NA 0.212 (0.099)
XXL-VLDL-L NA NA 0.316 (0.114) NA -0.156 (0.22) NA
XXL-VLDL-P 0.091 (0.071) 0.236 (0.089) 0.267 (0.1) 0.263 (0.088) -0.104 (0.173) 0.185 (0.098)
XXL-VLDL-PL 0.153 (0.082) 0.283 (0.096) 0.267 (0.11) 0.332 (0.095) -0.139 (0.178) 0.126 (0.124)
XXL-VLDL-TG 0.126 (0.078) 0.266 (0.096) 0.244 (0.108) 0.339 (0.097) 0.227 (0.171) 0.23 (0.123)
IDL/LDL traits
LDL-C 0.263 (0.053) 0.307 (0.066) 0.274 (0.05) 0.297 (0.063) 0.435 (0.072) 0.431 (0.067)
ApoB 0.365 (0.073) 0.472 (0.078) 0.381 (0.063) 0.375 (0.081) 0.624 (0.08) 0.565 (0.094)
LDL-D 0.306 (0.09) 0.413 (0.157) 0.467 (0.163) 0.271 (0.142) 0.294 (0.075) 0.193 (0.06)
S-LDL-C 0.271 (0.058) 0.342 (0.073) 0.343 (0.056) 0.273 (0.068) 0.498 (0.08) 0.274 (0.083)
S-LDL-L NA NA 0.354 (0.061) NA 0.449 (0.081) NA
S-LDL-P 0.355 (0.063) 0.366 (0.078) 0.397 (0.069) 0.329 (0.08) 0.49 (0.089) 0.581 (0.098)
M-LDL-C 0.283 (0.055) 0.313 (0.073) 0.299 (0.05) 0.244 (0.07) 0.474 (0.074) 0.297 (0.074)
M-LDL-CE 0.27 (0.055) 0.333 (0.077) 0.299 (0.051) 0.255 (0.071) 0.437 (0.081) 0.311 (0.077)
M-LDL-L NA NA 0.303 (0.053) NA 0.432 (0.079) NA
M-LDL-P 0.251 (0.057) 0.32 (0.071) 0.309 (0.054) 0.278 (0.07) 0.409 (0.072) 0.325 (0.078)
M-LDL-PL 0.343 (0.063) 0.337 (0.081) 0.316 (0.055) 0.318 (0.078) 0.457 (0.074) 0.353 (0.085)
L-LDL-C 0.251 (0.052) 0.29 (0.067) 0.303 (0.048) 0.231 (0.063) 0.45 (0.075) 0.309 (0.071)
L-LDL-CE 0.251 (0.054) 0.32 (0.068) 0.293 (0.052) 0.241 (0.066) 0.481 (0.074) 0.322 (0.077)
L-LDL-FC 0.251 (0.048) 0.214 (0.061) 0.301 (0.049) 0.214 (0.062) 0.427 (0.068) 0.289 (0.065)
L-LDL-L NA NA 0.289 (0.051) NA 0.412 (0.07) NA
L-LDL-P 0.281 (0.053) 0.321 (0.067) 0.29 (0.053) 0.244 (0.066) 0.42 (0.072) 0.351 (0.072)
L-LDL-PL 0.286 (0.05) 0.32 (0.067) 0.313 (0.052) 0.298 (0.065) 0.413 (0.074) 0.35 (0.076)
IDL-C 0.283 (0.056) 0.349 (0.068) 0.315 (0.053) 0.313 (0.07) 0.51 (0.072) 0.383 (0.068)
IDL-FC 0.283 (0.053) 0.334 (0.066) 0.337 (0.053) 0.314 (0.065) 0.422 (0.067) 0.367 (0.064)
IDL-L NA NA 0.329 (0.056) NA 0.494 (0.069) NA
IDL-P 0.331 (0.06) 0.44 (0.067) 0.343 (0.056) 0.371 (0.069) 0.463 (0.074) 0.328 (0.068)
IDL-PL 0.265 (0.055) 0.332 (0.066) 0.344 (0.056) 0.316 (0.066) 0.451 (0.072) 0.359 (0.066)
IDL-TG 0.233 (0.067) 0.371 (0.086) 0.605 (0.078) 0.337 (0.085) 0.315 (0.082) 0.215 (0.057)
HDL traits
HDL-C -0.017 (0.04) -0.167 (0.058) -0.17 (0.072) -0.167 (0.058) -0.096 (0.077) -0.085 (0.07)
ApoA1 0.094 (0.049) -0.06 (0.076) -0.069 (0.087) -0.167 (0.07) 0.005 (0.083) -0.051 (0.121)
HDL-D 0.079 (0.034) 0.062 (0.061) 0.102 (0.064) 0.088 (0.061) 0.099 (0.061) 0.096 (0.058)
S-HDL-L NA NA -0.174 (0.113) NA NA NA
S-HDL-P -0.173 (0.069) 0.018 (0.106) -0.171 (0.109) -0.235 (0.113) NA -0.049 (0.108)
S-HDL-TG 0.157 (0.061) 0.238 (0.085) 0.312 (0.105) 0.228 (0.086) 0.327 (0.105) 0.229 (0.076)
M-HDL-C -0.169 (0.054) -0.236 (0.082) -0.264 (0.097) -0.241 (0.077) -0.392 (0.098) -0.266 (0.084)
M-HDL-CE -0.166 (0.053) -0.23 (0.08) -0.271 (0.099) -0.238 (0.075) -0.394 (0.103) -0.23 (0.085)
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Appendix 3—table 4 continued
Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
M-HDL-FC -0.166 (0.055) -0.254 (0.086) -0.281 (0.098) -0.282 (0.087) -0.28 (0.102) -0.22 (0.1)
M-HDL-L NA NA -0.296 (0.113) NA -0.448 (0.122) NA
M-HDL-P -0.157 (0.056) -0.199 (0.09) -0.298 (0.112) -0.231 (0.086) -0.291 (0.136) -0.165 (0.131)
M-HDL-PL -0.143 (0.058) -0.183 (0.088) -0.285 (0.108) -0.183 (0.085) -0.321 (0.114) -0.203 (0.12)
L-HDL-C 0.086 (0.037) -0.009 (0.066) 0.031 (0.083) -0.032 (0.08) 0.003 (0.09) 0.006 (0.068)
L-HDL-CE 0.086 (0.038) -0.011 (0.067) 0.075 (0.077) -0.037 (0.076) 0.015 (0.091) -0.006 (0.068)
L-HDL-FC 0.09 (0.039) -0.005 (0.067) 0.079 (0.081) -0.019 (0.076) 0.041 (0.078) 0.027 (0.074)
L-HDL-L NA NA 0.074 (0.077) NA 0.068 (0.084) NA
L-HDL-P 0.081 (0.036) 0.046 (0.062) 0.075 (0.074) -0.01 (0.066) 0.066 (0.07) 0.078 (0.064)
L-HDL-PL 0.084 (0.039) 0 (0.067) 0.051 (0.082) -0.021 (0.071) 0.054 (0.075) 0.074 (0.071)
XL-HDL-C 0.163 (0.047) 0.122 (0.091) 0.136 (0.087) 0.132 (0.09) 0.02 (0.098) 0.161 (0.096)
XL-HDL-CE 0.139 (0.044) 0.106 (0.088) 0.122 (0.09) 0.148 (0.085) 0.038 (0.091) 0.336 (0.092)
XL-HDL-FC 0.135 (0.048) 0.065 (0.079) 0.133 (0.081) 0.027 (0.077) 0.159 (0.079) 0.052 (0.086)
XL-HDL-L NA NA 0.119 (0.075) NA 0.023 (0.078) NA
XL-HDL-P 0.115 (0.035) 0.087 (0.07) 0.12 (0.073) 0.129 (0.067) 0.16 (0.071) 0.15 (0.073)
XL-HDL-PL 0.101 (0.037) 0.064 (0.07) 0.11 (0.072) 0.121 (0.069) 0.141 (0.069) 0.088 (0.065)
XL-HDL-TG 0.074 (0.027) 0.107 (0.047) 0.126 (0.051) 0.118 (0.042) 0.156 (0.05) 0.114 (0.045)
Multivariable MR results
Appendix 3—table 5. Multivariable Mendelian randomization results (adjusted for HDL-C, LDL-C,
and TG).
Trait HDL-C LDL-C TG Subfraction
VLDL traits
VLDL-D -0.251 (0.052) 0.29 (0.037) 0.6 (0.087) -0.588 (0.094)
XS-VLDL-L -0.086 (0.046) 0.286 (0.077) 0.089 (0.099) 0.132 (0.119)
XS-VLDL-P -0.083 (0.045) 0.299 (0.078) 0.093 (0.106) 0.118 (0.125)
XS-VLDL-PL -0.083 (0.046) 0.249 (0.098) 0.112 (0.076) 0.159 (0.12)
XS-VLDL-TG -0.114 (0.046) 0.463 (0.079) 0.286 (0.173) -0.157 (0.187)
S-VLDL-C -0.267 (0.084) 0.754 (0.112) 1.033 (0.28) -1.035 (0.323)
S-VLDL-FC -0.195 (0.068) 0.898 (0.163) 0.935 (0.26) -1.027 (0.337)
S-VLDL-L -0.25 (0.072) 0.755 (0.112) 0.876 (0.233) -0.898 (0.28)
S-VLDL-P -0.31 (0.101) 0.819 (0.157) 1.209 (0.4) -1.245 (0.463)
S-VLDL-PL -0.168 (0.051) 0.673 (0.074) 0.626 (0.159) -0.613 (0.182)
S-VLDL-TG -0.499 (0.305) 0.906 (0.34) 2.532 (1.57) -2.628 (1.741)
M-VLDL-C -0.201 (0.068) 0.808 (0.127) 1.472 (0.424) -1.433 (0.451)
M-VLDL-CE -0.168 (0.061) 0.799 (0.111) 0.996 (0.249) -1.035 (0.293)
M-VLDL-FC -0.2 (0.072) 0.658 (0.089) 1.469 (0.417) -1.412 (0.444)
M-VLDL-L -0.355 (0.139) 0.602 (0.096) 1.787 (0.654) -1.878 (0.75)
M-VLDL-P -0.362 (0.124) 0.569 (0.08) 1.889 (0.676) -1.974 (0.745)
Continued on next page
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Appendix 3—table 5 continued
Trait HDL-C LDL-C TG Subfraction
M-VLDL-PL -0.332 (0.141) 0.722 (0.159) 1.996 (0.869) -2.012 (0.943)
M-VLDL-TG -0.408 (0.153) 0.432 (0.061) 1.974 (0.772) -2.133 (0.879)
L-VLDL-C -0.216 (0.063) 0.509 (0.046) 1.163 (0.254) -1.254 (0.297)
L-VLDL-CE -0.272 (0.072) 0.465 (0.04) 1.038 (0.242) -1.081 (0.282)
L-VLDL-FC -0.144 (0.059) 0.493 (0.044) 1.233 (0.27) -1.274 (0.308)
L-VLDL-L -0.228 (0.066) 0.414 (0.045) 1.17 (0.263) -1.277 (0.313)
L-VLDL-P -0.115 (0.056) 0.442 (0.046) 1.351 (0.317) -1.357 (0.344)
L-VLDL-PL -0.221 (0.111) 0.473 (0.07) 2.135 (0.948) -2.316 (1.112)
L-VLDL-TG -0.196 (0.066) 0.355 (0.05) 1.357 (0.322) -1.428 (0.372)
XL-VLDL-L -0.126 (0.049) 0.451 (0.04) 0.896 (0.159) -1.069 (0.203)
XL-VLDL-P -0.127 (0.053) 0.474 (0.043) 1.038 (0.183) -1.209 (0.238)
XL-VLDL-PL -0.138 (0.055) 0.5 (0.044) 1.052 (0.204) -1.214 (0.257)
XL-VLDL-TG -0.129 (0.049) 0.424 (0.04) 0.944 (0.167) -1.071 (0.205)
XXL-VLDL-L -0.228 (0.067) 0.444 (0.043) 0.978 (0.207) -1.355 (0.318)
XXL-VLDL-P 0.063 (0.076) 0.452 (0.05) 1.371 (0.384) -1.639 (0.502)
XXL-VLDL-PL -0.185 (0.056) 0.371 (0.042) 0.997 (0.185) -1.259 (0.262)
XXL-VLDL-TG -0.152 (0.059) 0.41 (0.04) 0.966 (0.19) -1.202 (0.262)
LDL/IDL traits
ApoB -0.084 (0.046) 0.8 (0.146) 0.427 (0.101) -0.532 (0.191)
LDL-D -0.057 (0.042) 0.367 (0.03) 0.21 (0.053) 0.145 (0.061)
S-LDL-C -0.062 (0.043) 0.614 (0.126) 0.261 (0.062) -0.282 (0.152)
S-LDL-L -0.06 (0.044) 0.584 (0.118) 0.266 (0.068) -0.251 (0.145)
S-LDL-P -0.033 (0.047) 0.589 (0.119) 0.29 (0.078) -0.266 (0.151)
M-LDL-C -0.082 (0.044) 0.623 (0.146) 0.203 (0.054) -0.271 (0.162)
M-LDL-CE -0.074 (0.043) 0.485 (0.167) 0.169 (0.059) -0.088 (0.188)
M-LDL-L -0.071 (0.044) 0.444 (0.171) 0.19 (0.063) -0.069 (0.191)
M-LDL-P -0.054 (0.044) 0.539 (0.153) 0.213 (0.063) -0.179 (0.174)
M-LDL-PL -0.081 (0.045) 0.747 (0.134) 0.232 (0.062) -0.407 (0.162)
L-LDL-C -0.071 (0.049) 0.437 (0.242) 0.167 (0.054) -0.059 (0.261)
L-LDL-CE -0.07 (0.048) 0.277 (0.301) 0.149 (0.065) 0.116 (0.321)
L-LDL-FC -0.112 (0.057) 0.184 (0.304) 0.163 (0.053) 0.223 (0.315)
L-LDL-L -0.075 (0.049) 0.229 (0.26) 0.146 (0.068) 0.167 (0.273)
L-LDL-P -0.083 (0.046) 0.33 (0.2) 0.128 (0.064) 0.084 (0.213)
L-LDL-PL -0.101 (0.046) 0.446 (0.177) 0.155 (0.057) -0.036 (0.195)
IDL-C -0.108 (0.057) 0.231 (0.215) 0.128 (0.064) 0.192 (0.229)
IDL-FC -0.107 (0.05) 0.23 (0.147) 0.123 (0.056) 0.19 (0.156)
IDL-L -0.1 (0.05) 0.274 (0.161) 0.123 (0.069) 0.148 (0.175)
IDL-P -0.101 (0.047) 0.269 (0.134) 0.109 (0.071) 0.153 (0.148)
IDL-PL -0.076 (0.048) 0.25 (0.162) 0.134 (0.071) 0.153 (0.18)
IDL-TG -0.083 (0.046) 0.314 (0.069) 0.103 (0.089) 0.11 (0.103)
HDL traits
ApoA1 0.345 (0.25) 0.544 (0.081) 0.334 (0.109) -0.481 (0.271)
HDL-D -0.442 (0.124) 0.421 (0.033) 0.111 (0.055) 0.333 (0.114)
Continued on next page
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Appendix 3—table 5 continued
Trait HDL-C LDL-C TG Subfraction
S-HDL-L -0.117 (0.046) 0.488 (0.044) 0.189 (0.054) -0.312 (0.106)
S-HDL-P -0.112 (0.046) 0.453 (0.035) 0.225 (0.056) -0.331 (0.095)
S-HDL-TG 0.002 (0.145) 0.314 (0.156) -0.007 (0.469) 0.253 (0.637)
M-HDL-C 0.179 (0.097) 0.36 (0.038) 0.147 (0.054) -0.508 (0.165)
M-HDL-CE 0.167 (0.087) 0.319 (0.036) 0.166 (0.055) -0.487 (0.157)
M-HDL-FC 0.339 (0.141) 0.436 (0.04) 0.247 (0.059) -0.649 (0.225)
M-HDL-L 0.27 (0.108) 0.362 (0.032) 0.299 (0.063) -0.606 (0.188)
M-HDL-P 0.302 (0.112) 0.386 (0.033) 0.371 (0.075) -0.694 (0.204)
M-HDL-PL 0.311 (0.117) 0.402 (0.033) 0.333 (0.07) -0.632 (0.191)
L-HDL-C -0.589 (0.211) 0.469 (0.039) 0.146 (0.055) 0.516 (0.213)
L-HDL-CE -0.602 (0.239) 0.477 (0.042) 0.137 (0.056) 0.519 (0.23)
L-HDL-FC -0.573 (0.177) 0.437 (0.034) 0.171 (0.054) 0.518 (0.181)
L-HDL-L -0.556 (0.193) 0.437 (0.034) 0.142 (0.055) 0.457 (0.189)
L-HDL-P -0.515 (0.198) 0.417 (0.03) 0.133 (0.056) 0.422 (0.191)
L-HDL-PL -0.53 (0.201) 0.415 (0.034) 0.152 (0.055) 0.443 (0.202)
XL-HDL-C -0.447 (0.182) 0.342 (0.036) 0.071 (0.079) 0.474 (0.223)
XL-HDL-CE -0.425 (0.146) 0.366 (0.038) 0.051 (0.069) 0.426 (0.177)
XL-HDL-FC -0.459 (0.147) 0.377 (0.031) 0.097 (0.062) 0.433 (0.16)
XL-HDL-L -0.405 (0.146) 0.364 (0.031) 0.077 (0.068) 0.358 (0.154)
XL-HDL-P -0.451 (0.134) 0.374 (0.03) 0.078 (0.064) 0.41 (0.139)
XL-HDL-PL -0.422 (0.119) 0.412 (0.033) 0.115 (0.055) 0.343 (0.118)
XL-HDL-TG -0.186 (0.073) 0.336 (0.035) 0.045 (0.086) 0.147 (0.074)
Appendix 3—table 6. Multivariable Mendelian randomization results (adjusted for ApoA1, ApoB,
and TG).
Trait ApoA1 ApoB TG Subfraction
VLDL traits
VLDL-D -0.227 (0.067) 0.545 (0.092) 0.208 (0.139) -0.32 (0.112)
XS-VLDL-L -0.123 (0.063) 0.53 (0.163) -0.121 (0.085) 0.084 (0.141)
XS-VLDL-P -0.121 (0.064) 0.553 (0.17) -0.123 (0.088) 0.061 (0.158)
XS-VLDL-PL -0.147 (0.066) 0.273 (0.138) 0.028 (0.05) 0.253 (0.135)
XS-VLDL-TG -0.102 (0.06) 0.762 (0.168) 0.069 (0.055) -0.248 (0.15)
S-VLDL-C -0.384 (0.141) 1.426 (0.354) 0.606 (0.351) -1.265 (0.568)
S-VLDL-FC -0.188 (0.077) 1.001 (0.235) 0.081 (0.053) -0.489 (0.213)
S-VLDL-L -0.46 (0.146) 1.776 (0.417) 0.7 (0.316) -1.629 (0.586)
S-VLDL-P -0.494 (0.159) 1.677 (0.386) 0.825 (0.372) -1.644 (0.606)
S-VLDL-PL -0.262 (0.097) 1.41 (0.343) 0.532 (0.261) -1.213 (0.478)
S-VLDL-TG -0.18 (0.069) 0.792 (0.121) 0.078 (0.051) -0.301 (0.108)
M-VLDL-C -0.157 (0.062) 0.867 (0.132) 0.085 (0.051) -0.373 (0.118)
M-VLDL-CE -0.221 (0.069) 1.224 (0.223) 0.47 (0.21) -0.995 (0.338)
M-VLDL-FC -0.222 (0.074) 0.902 (0.133) 0.482 (0.251) -0.799 (0.311)
M-VLDL-L -0.174 (0.065) 0.76 (0.104) 0.073 (0.05) -0.298 (0.098)
M-VLDL-P -0.181 (0.065) 0.764 (0.1) 0.077 (0.051) -0.312 (0.096)
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Appendix 3—table 6 continued
Trait ApoA1 ApoB TG Subfraction
M-VLDL-PL -0.159 (0.065) 0.776 (0.116) 0.08 (0.051) -0.297 (0.106)
M-VLDL-TG -0.263 (0.106) 0.724 (0.094) 0.547 (0.406) -0.806 (0.455)
L-VLDL-C -0.218 (0.084) 0.732 (0.101) 0.352 (0.278) -0.609 (0.337)
L-VLDL-CE -0.293 (0.079) 0.781 (0.096) 0.405 (0.189) -0.673 (0.217)
L-VLDL-FC -0.197 (0.069) 0.737 (0.094) 0.365 (0.25) -0.619 (0.291)
L-VLDL-L -0.194 (0.071) 0.666 (0.087) 0.289 (0.234) -0.532 (0.278)
L-VLDL-P -0.184 (0.061) 0.677 (0.086) 0.415 (0.217) -0.617 (0.229)
L-VLDL-PL -0.155 (0.063) 0.715 (0.095) 0.075 (0.051) -0.287 (0.104)
L-VLDL-TG -0.154 (0.062) 0.67 (0.083) 0.073 (0.05) -0.252 (0.091)
XL-VLDL-L -0.186 (0.066) 0.694 (0.088) 0.263 (0.19) -0.577 (0.249)
XL-VLDL-P -0.167 (0.061) 0.742 (0.088) 0.075 (0.05) -0.373 (0.109)
XL-VLDL-PL -0.191 (0.068) 0.712 (0.092) 0.271 (0.197) -0.583 (0.268)
XL-VLDL-TG -0.195 (0.068) 0.666 (0.087) 0.334 (0.21) -0.603 (0.248)
XXL-VLDL-L -0.173 (0.066) 0.732 (0.098) 0.088 (0.052) -0.402 (0.144)
XXL-VLDL-P -0.071 (0.065) 0.705 (0.097) 0.607 (0.321) -1.089 (0.449)
XXL-VLDL-PL -0.244 (0.082) 0.666 (0.091) 0.414 (0.257) -0.814 (0.344)
XXL-VLDL-TG -0.3 (0.091) 0.694 (0.095) 0.627 (0.306) -1.075 (0.402)
IDL/LDL traits
LDL-C -0.119 (0.062) 0.247 (0.167) 0.066 (0.054) 0.319 (0.182)
LDL-D -0.123 (0.06) 0.544 (0.091) -0.036 (0.087) 0.119 (0.071)
S-LDL-C -0.097 (0.06) 0.438 (0.216) 0.044 (0.051) 0.08 (0.238)
S-LDL-L -0.097 (0.063) 0.503 (0.268) 0.043 (0.051) -0.005 (0.29)
S-LDL-P -0.059 (0.103) 0.932 (0.597) -0.122 (0.112) -0.362 (0.596)
M-LDL-C -0.099 (0.065) 0.78 (1.034) -0.172 (0.425) -0.169 (0.909)
M-LDL-CE -0.157 (0.128) -0.346 (2.587) 0.195 (0.855) 0.854 (2.221)
M-LDL-L -0.123 (0.095) 0.247 (1.479) -0.001 (0.445) 0.32 (1.293)
M-LDL-P -0.134 (0.07) 0.13 (0.286) 0.053 (0.052) 0.432 (0.31)
M-LDL-PL -0.075 (0.077) 1.165 (0.868) -0.248 (0.253) -0.566 (0.839)
L-LDL-C -0.855 (1.68) -5.337 (13.402) 2.405 (5.735) 5.257 (11.72)
L-LDL-CE -0.151 (0.065) 0.129 (0.193) 0.061 (0.052) 0.461 (0.213)
L-LDL-FC -0.397 (0.219) -1.139 (1.395) 0.786 (0.711) 1.531 (1.189)
L-LDL-L -0.265 (0.148) -0.854 (1.42) 0.41 (0.51) 1.266 (1.188)
L-LDL-P -0.258 (0.153) -0.607 (1.225) 0.276 (0.402) 1.064 (1.029)
L-LDL-PL -0.312 (0.187) -0.741 (1.411) 0.39 (0.518) 1.227 (1.245)
IDL-C -0.3 (0.123) -0.334 (0.616) 0.276 (0.254) 0.769 (0.501)
IDL-FC -0.199 (0.069) 0.247 (0.118) 0.044 (0.049) 0.33 (0.127)
IDL-L -0.215 (0.089) 0.021 (0.409) 0.101 (0.15) 0.444 (0.328)
IDL-P -0.175 (0.075) 0.214 (0.172) 0.04 (0.051) 0.292 (0.173)
IDL-PL -0.183 (0.07) 0.159 (0.172) 0.031 (0.049) 0.406 (0.184)
IDL-TG -0.143 (0.075) 0.565 (0.146) -0.119 (0.087) 0.047 (0.135)
HDL traits
HDL-C -1.513 (1.109) 0.982 (0.314) 0.27 (0.291) 1.446 (1.112)
HDL-D -0.457 (0.138) 0.613 (0.073) 0.056 (0.049) 0.296 (0.1)
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Appendix 3—table 6 continued
Trait ApoA1 ApoB TG Subfraction
S-HDL-L -0.128 (0.059) 0.524 (0.062) 0.067 (0.05) -0.224 (0.087)
S-HDL-P -0.132 (0.059) 0.531 (0.059) 0.071 (0.05) -0.24 (0.083)
S-HDL-TG -0.11 (0.113) 0.595 (0.221) -0.057 (0.297) -0.044 (0.466)
M-HDL-C 0.091 (0.084) 0.459 (0.101) -0.1 (0.083) -0.442 (0.143)
M-HDL-CE 0.09 (0.078) 0.291 (0.083) 0.082 (0.05) -0.413 (0.137)
M-HDL-FC 0.148 (0.11) 0.378 (0.063) 0.066 (0.049) -0.408 (0.166)
M-HDL-L 0.133 (0.091) 0.491 (0.097) -0.029 (0.086) -0.485 (0.155)
M-HDL-P 0.129 (0.097) 0.501 (0.097) -0.004 (0.09) -0.472 (0.166)
M-HDL-PL 0.162 (0.107) 0.519 (0.096) -0.037 (0.087) -0.486 (0.171)
L-HDL-C -0.724 (0.232) 0.856 (0.132) 0.032 (0.093) 0.575 (0.204)
L-HDL-CE -0.761 (0.236) 0.899 (0.145) 0.004 (0.084) 0.61 (0.206)
L-HDL-FC -0.749 (0.174) 0.842 (0.102) 0.094 (0.05) 0.59 (0.148)
L-HDL-L -0.717 (0.217) 0.815 (0.12) 0.023 (0.089) 0.541 (0.184)
L-HDL-P -0.653 (0.191) 0.749 (0.104) 0.057 (0.049) 0.476 (0.155)
L-HDL-PL -0.679 (0.201) 0.774 (0.109) 0.05 (0.049) 0.51 (0.169)
XL-HDL-C -0.639 (0.194) 0.692 (0.095) -0.058 (0.086) 0.565 (0.196)
XL-HDL-CE -0.576 (0.2) 0.667 (0.096) -0.077 (0.086) 0.511 (0.206)
XL-HDL-FC -0.734 (0.174) 0.674 (0.073) 0.094 (0.052) 0.609 (0.159)
XL-HDL-L -0.652 (0.168) 0.733 (0.097) -0.06 (0.084) 0.481 (0.141)
XL-HDL-P -0.52 (0.147) 0.691 (0.094) -0.075 (0.084) 0.39 (0.135)
XL-HDL-PL -0.652 (0.151) 0.687 (0.076) 0.079 (0.051) 0.466 (0.12)
XL-HDL-TG -0.281 (0.111) 0.539 (0.09) -0.152 (0.092) 0.165 (0.086)
Q-statistics for multivariable Mendelian randomization
Here we provide the list of modified Cochran’s Q-statistics for the multivariable MR analyses
(Appendix 3—tables 7 and 8).
Appendix 3—table 7. Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian
randomization analyses (adjusted for HDL-C, LDL-C, and TG).
DF is short for degrees of freedom.
Trait DF HDL-C LDL-C TG Subfraction
VLDL traits
VLDL-D 432 7640.8 (0) 1918.9 (7.9e-186) 877.6 (1.4e-32) 840.2 (1.6e-28)
XS-VLDL-L 436 7983.9 (0) 1104.9 (1.1e-59) 1935.8 (2.2e-187) 926 (1.9e-37)
XS-VLDL-P 436 7927.8 (0) 1066.6 (1.1e-54) 1814 (4.8e-167) 893.6 (9.6e-34)
XS-VLDL-PL 435 8291.5 (0) 968.1 (1.4e-42) 2771.5 (0) 849.8 (4.3e-29)
XS-VLDL-TG 431 7549.8 (0) 894.4 (1.3e-34) 739.5 (1.3e-18) 682.5 (1.2e-13)
S-VLDL-C 429 8598.1 (0) 652.6 (1.7e-11) 1220.7 (4.6e-77) 541.3 (0.00018)
S-VLDL-FC 434 7861.2 (0) 576 (5.4e-06) 519.4 (0.003) 507.9 (0.0082)
S-VLDL-L 438 7105.3 (0) 626 (8.5e-09) 525.2 (0.0026) 514.3 (0.0069)
S-VLDL-P 438 6686.5 (0) 616.5 (3.6e-08) 515.6 (0.0061) 507.3 (0.012)
S-VLDL-PL 437 7589.1 (0) 702.8 (1e-14) 591.5 (1.1e-06) 555.1 (0.00011)
S-VLDL-TG 437 7658.7 (0) 612.7 (5.3e-08) 498.9 (0.021) 494.5 (0.03)
Continued on next page
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Trait DF HDL-C LDL-C TG Subfraction
M-VLDL-C 432 9167.8 (0) 740.8 (1.3e-18) 558.9 (3.5e-05) 551.5 (8.3e-05)
M-VLDL-CE 432 8055.2 (0) 705.9 (1.6e-15) 556.6 (4.6e-05) 539.7 (0.00031)
M-VLDL-FC 436 8272.8 (0) 814.8 (2.7e-25) 528.3 (0.0016) 519.1 (0.0037)
M-VLDL-L 429 7109.2 (0) 1269.2 (5.5e-84) 532.6 (0.00047) 515.9 (0.0025)
M-VLDL-P 436 8260.7 (0) 2059.5 (2.1e-208) 527.5 (0.0017) 516.8 (0.0046)
M-VLDL-PL 435 6849.2 (0) 599.6 (2.6e-07) 496.8 (0.021) 493.5 (0.027)
M-VLDL-TG 436 6123.7 (0) 9854.8 (0) 532.3 (0.0011) 521 (0.0031)
L-VLDL-C 435 8617.2 (0) 8966 (0) 654.7 (4.3e-11) 561.5 (3.9e-05)
L-VLDL-CE 434 6636.6 (0) 11134 (0) 581.6 (2.6e-06) 539.5 (0.00041)
L-VLDL-FC 431 7779.6 (0) 6691 (0) 595.1 (2.5e-07) 562.7 (1.9e-05)
L-VLDL-L 434 8104.9 (0) 5191.4 (0) 560.3 (3.9e-05) 548.6 (0.00015)
L-VLDL-P 435 2308 (5.1e-252) 10360.3 (0) 545.4 (0.00024) 537.9 (0.00054)
L-VLDL-PL 430 8155.4 (0) 1310.8 (8.6e-90) 491.8 (0.021) 489.7 (0.024)
L-VLDL-TG 438 8581.8 (0) 4800.1 (0) 569.1 (2.3e-05) 559.2 (7.5e-05)
XL-VLDL-L 437 8686.8 (0) 8322.2 (0) 674.7 (1.9e-12) 620.2 (1.7e-08)
XL-VLDL-P 431 8550.2 (0) 2459.4 (2e-280) 608.3 (3.6e-08) 588.6 (6.3e-07)
XL-VLDL-PL 431 7478.2 (0) 5042.5 (0) 613.3 (1.7e-08) 591.6 (4.1e-07)
XL-VLDL-TG 433 8237.3 (0) 9628.9 (0) 651.8 (4.6e-11) 618.3 (1.1e-08)
XXL-VLDL-L 439 8476.2 (0) 10436.4 (0) 652.9 (1.3e-10) 570.7 (2.2e-05)
XXL-VLDL-P 437 1291.3 (2.8e-85) 9987.4 (0) 540.3 (0.00053) 529.5 (0.0016)
XXL-VLDL-PL 436 9631.8 (0) 11287.1 (0) 641.6 (4.8e-10) 595.5 (5.3e-07)
XXL-VLDL-TG 429 7809.4 (0) 9476.4 (0) 595.6 (1.7e-07) 564 (1.2e-05)
LDL/IDL traits
ApoB 435 9220.8 (0) 550.1 (0.00014) 1809.7 (1.2e-166) 535.1 (0.00072)
LDL-D 429 2909.2 (0) 3918.8 (0) 2706 (0) 1426.1 (2.9e-107)
S-LDL-C 431 8189.7 (0) 569.8 (7.8e-06) 4880.9 (0) 564.1 (1.6e-05)
S-LDL-L 435 8403.8 (0) 574.4 (7.8e-06) 3931.2 (0) 564.3 (2.7e-05)
S-LDL-P 431 7371.4 (0) 547.1 (0.00012) 3144.7 (0) 537.9 (0.00034)
M-LDL-C 430 9723.7 (0) 570.9 (5.8e-06) 6568.6 (0) 562.9 (1.6e-05)
M-LDL-CE 432 8442.1 (0) 558.3 (3.8e-05) 5773.6 (0) 549.1 (0.00011)
M-LDL-L 430 8801.7 (0) 555.4 (4e-05) 5176.1 (0) 548.2 (9.5e-05)
M-LDL-P 429 8798.9 (0) 541.6 (0.00018) 5049.7 (0) 535.2 (0.00035)
M-LDL-PL 436 7981.7 (0) 573.9 (9.6e-06) 4304.8 (0) 558.9 (6e-05)
L-LDL-C 432 8865.2 (0) 567.7 (1.2e-05) 6179.8 (0) 567 (1.3e-05)
L-LDL-CE 433 8464.3 (0) 558.7 (4.1e-05) 5731.3 (0) 555.6 (5.9e-05)
L-LDL-FC 431 7481.1 (0) 580.6 (1.9e-06) 6760.8 (0) 580.2 (2e-06)
L-LDL-L 433 8486.8 (0) 604.5 (8.9e-08) 5755.8 (0) 601.8 (1.3e-07)
L-LDL-P 434 8310.7 (0) 592.1 (6.3e-07) 5553.3 (0) 584.9 (1.7e-06)
L-LDL-PL 435 8341.4 (0) 588.5 (1.2e-06) 5327.8 (0) 577.4 (5.3e-06)
IDL-C 434 7873.9 (0) 645.5 (1.7e-10) 6336 (0) 642.1 (2.9e-10)
IDL-FC 432 8036 (0) 729.5 (1.4e-17) 6630.5 (0) 725.6 (3e-17)
IDL-L 434 7869.8 (0) 694.5 (2.4e-14) 5198.3 (0) 689 (7e-14)
IDL-P 436 9660.5 (0) 736.7 (9e-18) 5002 (0) 726.6 (7.1e-17)
Continued on next page
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Appendix 3—table 7 continued
Trait DF HDL-C LDL-C TG Subfraction
IDL-PL 431 8432.6 (0) 680.6 (1.7e-13) 5023 (0) 677.4 (3e-13)
IDL-TG 436 7741.2 (0) 1077.5 (4.2e-56) 1992.9 (4.9e-197) 931.6 (4.4e-38)
HDL traits
ApoA1 434 494.1 (0.024) 511.5 (0.006) 932.1 (1.8e-38) 492 (0.028)
HDL-D 438 783.5 (6.6e-22) 8500 (0) 5713.2 (0) 860.1 (9.4e-30)
S-HDL-L 438 3067.3 (0) 4414.6 (0) 3763.2 (0) 882.2 (3.7e-32)
S-HDL-P 438 2592.4 (1.1e-301) 7652.1 (0) 3097.3 (0) 951.1 (4.9e-40)
S-HDL-TG 425 896.9 (6.9e-36) 641.3 (5.2e-11) 540.1 (0.00013) 523 (8e-04)
M-HDL-C 437 957.6 (5.5e-41) 10172.4 (0) 4875.5 (0) 628.3 (4.9e-09)
M-HDL-CE 434 955.3 (3.2e-41) 1383.1 (1.7e-99) 4355.4 (0) 648.3 (1e-10)
M-HDL-FC 432 759.4 (2.4e-20) 2989.1 (0) 3512.2 (0) 538.2 (0.00037)
M-HDL-L 435 914.2 (3e-36) 11535.3 (0) 2327.7 (1.7e-255) 570.3 (1.3e-05)
M-HDL-P 434 997.6 (2.3e-46) 10709.6 (0) 1942.9 (3.2e-189) 561.3 (3.4e-05)
M-HDL-PL 434 977.8 (6.3e-44) 9439.9 (0) 2566 (1.8e-298) 581.3 (2.7e-06)
L-HDL-C 434 580 (3.2e-06) 1257.1 (4.4e-81) 4502.7 (0) 604.3 (1.1e-07)
L-HDL-CE 434 549 (0.00014) 930.2 (3e-38) 5517.2 (0) 557.2 (5.6e-05)
L-HDL-FC 441 627.6 (1.2e-08) 8415.3 (0) 3594 (0) 658.4 (7.9e-11)
L-HDL-L 434 603.6 (1.2e-07) 6743.8 (0) 5314.7 (0) 623.7 (5.7e-09)
L-HDL-P 432 601.1 (1.2e-07) 7769.3 (0) 6024.6 (0) 633.2 (8.6e-10)
L-HDL-PL 434 584.5 (1.8e-06) 9935.5 (0) 3544.3 (0) 611.3 (3.8e-08)
XL-HDL-C 430 732.9 (3.9e-18) 10426.6 (0) 2077.7 (1.4e-213) 686.9 (4e-14)
XL-HDL-CE 430 771.4 (9.3e-22) 8564.4 (0) 2457 (2.2e-280) 711.4 (3.3e-16)
XL-HDL-FC 432 761.8 (1.4e-20) 11265.2 (0) 2549.4 (3.1e-296) 770.9 (1.9e-21)
XL-HDL-L 429 767.6 (1.6e-21) 11490.7 (0) 2355.7 (1.2e-262) 784.6 (3.4e-23)
XL-HDL-P 433 724.9 (4.6e-17) 11372.5 (0) 2539.9 (3.9e-294) 798.5 (4.8e-24)
XL-HDL-PL 443 809.7 (7.8e-24) 10093.1 (0) 5762 (0) 895.4 (7.5e-33)
XL-HDL-TG 432 1849.1 (3.9e-174) 2635.9 (6.5e-312) 2240.8 (2.9e-241) 1267.8 (4.4e-83)
Appendix 3—table 8. Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian
randomization analyses (adjusted for ApoA1, ApoB, and TG).
DF is short for degrees of freedom.
Trait DF ApoA1 ApoB TG Subfraction
VLDL traits
VLDL-D 297 1194.1 (9.1e-108) 550 (2.4e-17) 573.7 (8.2e-20) 606.7 (2.1e-23)
XS-VLDL-L 295 1185.1 (6.7e-107) 927 (2e-66) 1151.3 (2.2e-101) 887.9 (1.1e-60)
XS-VLDL-P 295 1194.9 (1.7e-108) 900 (1.9e-62) 895.5 (8.7e-62) 826.7 (6.4e-52)
XS-VLDL-PL 296 1148.5 (1.2e-100) 973.9 (3.2e-73) 2104.2 (1.4e-269) 961.4 (2.5e-71)
XS-VLDL-TG 302 1263.7 (1.1e-117) 757.9 (4.7e-41) 1308.1 (4.4e-125) 976.5 (4.6e-72)
S-VLDL-C 290 988.8 (4.4e-77) 394 (4.5e-05) 459.8 (7.8e-10) 402.6 (1.3e-05)
S-VLDL-FC 296 1092 (1.4e-91) 904 (8.6e-63) 1238.7 (2.1e-115) 1010.4 (8.1e-79)
S-VLDL-L 301 1107.9 (1.1e-92) 412.3 (2.1e-05) 420.8 (5.9e-06) 384.7 (0.00078)
S-VLDL-P 301 1116.6 (4.6e-94) 424.8 (3.3e-06) 401.3 (9.4e-05) 380.6 (0.0013)
Continued on next page
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Appendix 3—table 8 continued
Trait DF ApoA1 ApoB TG Subfraction
S-VLDL-PL 299 1096 (2.3e-91) 428.9 (1.2e-06) 446 (7.1e-08) 432.1 (7.1e-07)
S-VLDL-TG 300 1152.4 (4.3e-100) 908.5 (1.8e-62) 1453.4 (1.8e-150) 1303.1 (7.1e-125)
M-VLDL-C 298 1171.2 (1e-103) 824 (7.3e-51) 1480 (8.9e-156) 1212.5 (1.8e-110)
M-VLDL-CE 298 1185.4 (4.9e-106) 564.4 (1.1e-18) 468.9 (9.2e-10) 431.6 (6.3e-07)
M-VLDL-FC 298 1190.4 (7.4e-107) 899.8 (1.1e-61) 415.2 (8.1e-06) 398.8 (8.4e-05)
M-VLDL-L 298 1144.1 (2.4e-99) 869.8 (2.4e-57) 1381 (1e-138) 1237.4 (1.4e-114)
M-VLDL-P 297 1121.3 (5.7e-96) 821.1 (1.1e-50) 1250.5 (4.6e-117) 1206.7 (8.1e-110)
M-VLDL-PL 298 1149.9 (2.8e-100) 843.2 (1.5e-53) 1391.8 (1.5e-140) 1226.3 (9.8e-113)
M-VLDL-TG 296 1187.4 (5.8e-107) 717.3 (5.8e-37) 366.3 (0.0033) 360.6 (0.006)
L-VLDL-C 295 1196.5 (9.1e-109) 820 (5.6e-51) 462.5 (1.5e-09) 376.9 (0.00088)
L-VLDL-CE 302 1183.1 (1.8e-104) 844.6 (7.4e-53) 541.8 (7.2e-16) 441.7 (2.6e-07)
L-VLDL-FC 295 1172.3 (8.2e-105) 851.6 (1.9e-55) 460.8 (2.1e-09) 406.2 (1.8e-05)
L-VLDL-L 295 1163.6 (2.2e-103) 797 (8.8e-48) 406.5 (1.7e-05) 391.5 (0.00014)
L-VLDL-P 293 1160.2 (2e-103) 809.5 (5.9e-50) 420.2 (1.5e-06) 407.9 (1e-05)
L-VLDL-PL 296 1292 (2.6e-124) 833.4 (1.3e-52) 1216.5 (9.7e-112) 1098.9 (1.1e-92)
L-VLDL-TG 294 1150.8 (1.3e-101) 1213.6 (7e-112) 1262.6 (5.2e-120) 1162.8 (1.5e-103)
XL-VLDL-L 294 1196 (5.4e-109) 829.4 (1.6e-52) 442 (4.9e-08) 423.6 (1.1e-06)
XL-VLDL-P 294 1265.9 (1.4e-120) 1180.9 (1.6e-106) 1202.2 (5.2e-110) 982.1 (5.4e-75)
XL-VLDL-PL 296 1199.1 (6.9e-109) 874.2 (1.9e-58) 421.2 (2.3e-06) 405.6 (2.3e-05)
XL-VLDL-TG 296 1184.3 (1.8e-106) 828.6 (5.9e-52) 430.8 (4.9e-07) 430.1 (5.5e-07)
XXL-VLDL-L 304 1119.2 (1.2e-93) 1041.9 (1.6e-81) 900.9 (2e-60) 699.6 (3.2e-33)
XXL-VLDL-P 303 1148 (1.7e-98) 876.4 (4e-57) 382.2 (0.0013) 366 (0.0076)
XXL-VLDL-PL 303 1203 (2.1e-107) 775.1 (4e-43) 438.1 (5.8e-07) 376.5 (0.0025)
XXL-VLDL-TG 303 1183 (3.7e-104) 881.8 (6.6e-58) 393.7 (0.00034) 372.7 (0.0039)
LDL/IDL traits
LDL-C 293 1198.7 (9.6e-110) 938.8 (1.1e-68) 1060.2 (2.1e-87) 917.6 (1.5e-65)
LDL-D 296 1325.2 (6.7e-130) 747.9 (5.9e-41) 879.1 (3.7e-59) 1163.5 (4.6e-103)
S-LDL-C 296 1195.3 (2.9e-108) 706 (1.6e-35) 1426 (4.1e-147) 686.4 (4.8e-33)
S-LDL-L 296 1054.7 (1.1e-85) 608 (1e-23) 1519.6 (2.2e-163) 586.4 (2.5e-21)
S-LDL-P 297 852.9 (3.6e-55) 438.7 (1.6e-07) 954.7 (4.5e-70) 440.1 (1.3e-07)
M-LDL-C 296 1210.9 (8e-111) 396.2 (8.6e-05) 409 (1.4e-05) 398.9 (6e-05)
M-LDL-CE 295 1204.3 (4.8e-110) 350.8 (0.014) 361.7 (0.0048) 351.3 (0.013)
M-LDL-L 296 1212 (5.3e-111) 370 (0.0022) 392.3 (0.00015) 371.6 (0.0019)
M-LDL-P 297 1125.4 (1.2e-96) 623.9 (2.3e-25) 911.4 (1.3e-63) 582.4 (9.6e-21)
M-LDL-PL 299 1172.5 (1.2e-103) 399.3 (9.1e-05) 434.9 (4.5e-07) 396.2 (0.00014)
L-LDL-C 300 1174.6 (1.1e-103) 325.5 (0.15) 325.5 (0.15) 325.5 (0.15)
L-LDL-CE 299 1179.5 (9e-105) 769.8 (3e-43) 902.5 (7.7e-62) 743.8 (8.4e-40)
L-LDL-FC 295 1161 (5.8e-103) 322.4 (0.13) 323.2 (0.12) 322.3 (0.13)
L-LDL-L 300 1172.3 (2.6e-103) 336.9 (0.07) 349.6 (0.026) 340.3 (0.055)
L-LDL-P 300 1185.4 (2e-105) 352.1 (0.021) 378.4 (0.0014) 355.4 (0.015)
L-LDL-PL 296 1155.2 (9.8e-102) 343.2 (0.031) 360.1 (0.0063) 344.5 (0.027)
IDL-C 296 1181.7 (4.9e-106) 426.5 (9.8e-07) 427.6 (8.3e-07) 427.7 (8.1e-07)
IDL-FC 298 1096.5 (9.9e-92) 986.9 (1.1e-74) 1075.8 (1.9e-88) 975.4 (6.1e-73)
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Trait DF ApoA1 ApoB TG Subfraction
IDL-L 296 1176.1 (4e-105) 516.7 (3.3e-14) 531 (1.4e-15) 521.4 (1.2e-14)
IDL-P 297 1094.8 (9.5e-92) 910.9 (1.5e-63) 1103.9 (3.5e-93) 890.2 (1.6e-60)
IDL-PL 297 1107.8 (8.3e-94) 798.9 (1.3e-47) 931.6 (1.3e-66) 785.6 (8.6e-46)
IDL-TG 302 1060.8 (5.4e-85) 1052.1 (1.2e-83) 1092.6 (5.6e-90) 1118.3 (4.7e-94)
HDL traits
HDL-C 298 318.7 (0.2) 336.3 (0.063) 329.1 (0.1) 318.6 (0.2)
HDL-D 300 637.4 (1.9e-26) 1156.6 (9.1e-101) 2305.2 (1.3e-305) 1183.8 (3.5e-105)
S-HDL-L 299 1597.7 (4.8e-176) 1222.5 (8.2e-112) 1916.4 (1.5e-233) 1057 (3.1e-85)
S-HDL-P 299 1666.8 (2.5e-188) 1249.4 (2.9e-116) 2146.5 (3.4e-276) 1103.3 (1.6e-92)
S-HDL-TG 299 899 (2.5e-61) 464.9 (2.4e-09) 464.5 (2.6e-09) 457.6 (9.2e-09)
M-HDL-C 299 1145.2 (3.2e-99) 768.2 (4.9e-43) 951.8 (4e-69) 786.8 (1.5e-45)
M-HDL-CE 299 1201.9 (2e-108) 1183.9 (1.7e-105) 2139.7 (6.4e-275) 843.9 (1.9e-53)
M-HDL-FC 298 881.1 (5.6e-59) 1252 (5.5e-117) 1989.1 (2.4e-247) 660.1 (1.8e-29)
M-HDL-L 299 1059 (1.5e-85) 766.4 (8.7e-43) 920.6 (1.7e-64) 672.5 (8.6e-31)
M-HDL-P 298 990.2 (3.5e-75) 760.4 (3.4e-42) 1027.6 (6.2e-81) 613.7 (4.7e-24)
M-HDL-PL 295 929.5 (8.3e-67) 763.9 (2.7e-43) 1057.2 (2.3e-86) 588.3 (1.1e-21)
L-HDL-C 299 579.3 (4.1e-20) 623.2 (5.7e-25) 639.6 (7.3e-27) 617.8 (2.3e-24)
L-HDL-CE 299 612.2 (1e-23) 650.7 (3.6e-28) 690.4 (5.5e-33) 644 (2.2e-27)
L-HDL-FC 308 581.7 (4.4e-19) 857.5 (2.6e-53) 1213.3 (1.4e-107) 915.8 (1.3e-61)
L-HDL-L 299 655.9 (8.7e-29) 747.7 (2.6e-40) 670.7 (1.4e-30) 713.2 (7.5e-36)
L-HDL-P 298 591.3 (1.5e-21) 934 (9.9e-67) 1269.7 (6.2e-120) 956.8 (3.9e-70)
L-HDL-PL 299 580 (3.4e-20) 863.5 (3.3e-56) 1262.4 (2.1e-118) 891.8 (2.8e-60)
XL-HDL-C 298 475.3 (2.7e-10) 734 (1e-38) 976.1 (4.9e-73) 554 (1.3e-17)
XL-HDL-CE 299 472.9 (5.4e-10) 736.9 (6.7e-39) 1117.4 (9e-95) 517.5 (6.5e-14)
XL-HDL-FC 295 527.8 (2.1e-15) 1182.8 (1.6e-106) 2169.4 (3.1e-282) 677.3 (4.3e-32)
XL-HDL-L 298 555.2 (9.6e-18) 701.2 (1.6e-34) 1014 (7.9e-79) 775.3 (3.4e-44)
XL-HDL-P 300 578.9 (6.3e-20) 744.5 (1.1e-39) 1015.5 (1.6e-78) 751.3 (1.4e-40)
XL-HDL-PL 306 604.9 (7.8e-22) 1153.9 (1.4e-98) 1899 (1.5e-227) 909.3 (3.7e-61)
XL-HDL-TG 300 702.2 (2.8e-34) 779.8 (2.2e-44) 1140.8 (3.2e-98) 1399.2 (3.7e-141)
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Appendix 4
Diagnostic plots and the genetic markers
As mentioned above, RAPS is more robust against invalid instruments than other statistical methods
for univariable MR, but it still needs the InSIDE assumption to be approximately satisfied.
Zhao et al., 2019b described two diagnostic plots RAPS that checks whether there is clear evidence
that the InSIDE assumption is violated. Here, we report these plots for HDL-C and M-HDL-P in differ-
ent studies (Appendix 4—figures 1 and 2). Notice that a lack of evidence to falsify the InSIDE









































































































































































































































































Appendix 4—figure 2. Diagnostic plots for M-HDL-P (selection: Davis; exposure: Kettunen; out-
come: UK Biobank).
Genetic markers for M-HDL-P and S-HDL-P
We can further assess the validity of the InSIDE assumption for M-HDL-P and S-HDL-P but examining
the associations of their genetic instruments with the traditional lipid risk factors and other subfrac-
tion traits. We meta-analyzed the summary results in the two lipidome GWAS (Davis and Kettunen)
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and obtained SNPs that are associated with S-HDL-P and M-HDL-P (p-value  5 10 8; the results
are LD-clumped). The next two Tables show some information about these genetic markers and their
associations with other traits (Appendix 4—table 1 and 2).
Appendix 4—figures 3 and 4 shows how adjusting for LDL-C and TG changes the effects of the
selected SNPs for S-HDL-P and M-HDL-P on CAD. The adjusted effect on CAD is obtained by origi-
nal effect on CAD – 0.45 * effect on LDL-C – 0.25 * effect on TG. After the adjustment, the associa-
tions of the genetic variants with CAD generally became closer to the fitted lines that correspond to
the estimated effects of S-HDL-P and M-HDL-P.
Appendix 4—table 1. List of SNPs associated with M-HDL-P.




P HDL-C LDL-C TG CAD
rs11208004 1 DOCK7 -0.039 ** -0.075
***






































































-0.024 ** -0.009 -0.016
rs737337 19 DOCK6 -0.047 . -0.087
***
-0.081 ** -0.058 * -0.056
***
-0.007 -0.011 -0.038 .

























Appendix 4—table 2. List of SNPs associated with S-HDL-P.




P HDL-C LDL-C TG CAD
rs780094 2 GCKR -0.074
***
-0.034 * -0.04 ** -0.034 * -0.011 . -0.021 ** -0.110
***
-0.005
rs10935473 3 ST3GAL6-AS1 -0.052
***
-0.014 -0.029 . -0.031 * -0.009 . -0.003 -0.005 -0.007
rs4936363 11 SIK3 -0.064
***




















































Zhao et al. eLife 2021;10:e58361. DOI: https://doi.org/10.7554/eLife.58361 43 of 47


















0.00 0.05 0.10 0.15














Appendix 4—figure 3. Scatter-plots for S-HDL-P with the effects on CAD adjusted for LDL-C and
TG. Red lines correspond the fitted effects of S-HDL-P in multivariable MR.
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Appendix 4—figure 4. Scatter-plots for M-HDL-P with the effects on CAD adjusted for LDL-C and
TG. Red lines correspond the fitted effects of M-HDL-P in multivariable MR.
Gene expression
Here we provide evidence of variant-gene associations from Quantatitive Trait Locus (QTL) analyses
in the GTEx project (Appendix 4—table 3).
Appendix 4—table 3. Tissue-specific gene expressions associated with the 4 discovered genetic
markers in the GTEx project.
SNP.Id Type
Gene.
Symbol Variant.Id p value Effect Tissue
rs838880 eQTL SCARB1 chr12_124777047_C_T_b38 1.5E-08 -0.20 Cells - Cultured fibroblasts
rs838880 sQTL SCARB1 chr12_124777047_C_T_b38 4.1E-06 -0.34 Testis
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 3.8E-43 0.99 Artery - Tibial
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 6.4E-35 0.93 Adipose - Subcutaneous
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 6.4E-35 0.93 Adipose - Subcutaneous
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 1.6E-27 0.95 Esophagus - Muscularis
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 3.2E-20 1.10 Colon - Sigmoid
Continued on next page
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Appendix 4—table 3 continued
SNP.Id Type
Gene.
Symbol Variant.Id p value Effect Tissue
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 1.1E-17 0.93 Esophagus - Gastroesophageal
Junction
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 1.8E-09 0.81 Artery - Coronary
rs737337 sQTL DOCK6 chr19_11236817_T_C_b38 1.2E-07 -0.49 Thyroid
rs737337 sQTL KANK2 chr19_11236817_T_C_b38 4.4E-07 0.43 Artery - Tibial
rs737337 sQTL KANK2 chr19_11236817_T_C_b38 3.5E-06 0.55 Heart - Left Ventricle
rs2943641 eQTL IRS1 chr2_226229029_T_C_b38 1.4E-16 -0.30 Adipose - Subcutaneous
rs2943641 eQTL IRS1 chr2_226229029_T_C_b38 6.1E-12 -0.23 Adipose - Visceral (Omentum)
rs2943641 eQTL RP11-
395N3.2
chr2_226229029_T_C_b38 3.5E-09 -0.23 Adipose - Subcutaneous
rs2943641 eQTL RP11-
395N3.1
chr2_226229029_T_C_b38 2.1E-07 -0.23 Adipose - Subcutaneous
rs2943641 eQTL RP11-
395N3.2
chr2_226229029_T_C_b38 2.3E-06 -0.19 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 4.4E-22 -0.27 Muscle - Skeletal
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.6E-16 -0.27 Adipose - Subcutaneous
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.2E-15 -0.28 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 3.2E-15 -0.42 Heart - Atrial Appendage
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 7.2E-14 -0.25 Artery - Tibial
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.8E-12 -0.27 Nerve - Tibial
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 7.3E-12 -0.26 Esophagus - Muscularis
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 2.0E-11 -0.29 Colon - Transverse
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 4.1E-11 -0.32 Colon - Sigmoid
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.2E-09 -0.26 Artery - Aorta
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 4.2E-09 -0.29 Heart - Left Ventricle
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 5.0E-09 -0.22 Thyroid
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.7E-08 -0.29 Stomach
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 4.3E-08 -0.24 Lung
rs6065904 eQTL NEURL2 chr20_45906012_G_A_b38 6.6E-08 -0.26 Adipose - Subcutaneous
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 6.8E-08 -0.33 Liver
rs6065904 eQTL CTSA chr20_45906012_G_A_b38 4.0E-07 -0.14 Nerve - Tibial
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 5.3E-07 -0.37 Spleen
rs6065904 eQTL NEURL2 chr20_45906012_G_A_b38 5.6E-07 -0.26 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 8.9E-07 -0.46 Small Intestine - Terminal Ileum
rs6065904 eQTL RP3-
337O18.9
chr20_45906012_G_A_b38 1.8E-06 -0.22 Adipose - Subcutaneous
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 2.9E-06 -0.31 Nerve - Tibial
rs6065904 eQTL DNTTIP1 chr20_45906012_G_A_b38 3.1E-06 -0.17 Artery - Tibial
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 4.5E-06 -0.27 Skin - Sun Exposed (Lower leg)
rs6065904 eQTL SNX21 chr20_45906012_G_A_b38 4.8E-06 -0.15 Esophagus - Muscularis
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 8.9E-06 -0.27 Skin - Not Sun Exposed (Suprapubic)
rs6065904 eQTL DNTTIP1 chr20_45906012_G_A_b38 1.0E-05 -0.14 Nerve - Tibial
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.1E-05 -0.27 Prostate
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.3E-05 -0.26 Pituitary
Continued on next page
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Appendix 4—table 3 continued
SNP.Id Type
Gene.
Symbol Variant.Id p value Effect Tissue
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.4E-05 -0.21 Esophagus - Gastroesophageal
Junction
rs6065904 eQTL SNX21 chr20_45906012_G_A_b38 1.5E-05 -0.16 Esophagus - Mucosa
rs6065904 eQTL SNX21 chr20_45906012_G_A_b38 1.7E-05 -0.23 Colon - Sigmoid
rs6065904 eQTL SNX21 chr20_45906012_G_A_b38 1.7E-05 -0.17 Thyroid
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 2.6E-05 -0.21 Breast - Mammary Tissue
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 2.9E-05 -0.23 Artery - Tibial
rs6065904 eQTL NEURL2 chr20_45906012_G_A_b38 3.2E-05 -0.21 Thyroid
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 3.7E-05 -0.17 Testis
rs6065904 eQTL CTSA chr20_45906012_G_A_b38 4.4E-05 -0.11 Skin - Not Sun Exposed (Suprapubic)
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 5.8E-05 -0.23 Muscle - Skeletal
rs6065904 eQTL NEURL2 chr20_45906012_G_A_b38 8.2E-05 -0.27 Heart - Atrial Appendage
rs6065904 eQTL SNX21 chr20_45906012_G_A_b38 8.4E-05 -0.17 Artery - Aorta
rs6065904 eQTL NEURL2 chr20_45906012_G_A_b38 9.5E-05 -0.24 Artery - Aorta
rs6065904 eQTL WFDC3 chr20_45906012_G_A_b38 9.5E-05 -0.31 Artery - Aorta
rs6065904 eQTL RP3-
337O18.9
chr20_45906012_G_A_b38 9.5E-05 -0.29 Heart - Atrial Appendage
rs6065904 eQTL PLTP chr20_45906012_G_A_b38 1.2E-04 -0.15 Skin - Sun Exposed (Lower leg)
rs6065904 eQTL WFDC13 chr20_45906012_G_A_b38 1.5E-04 0.28 Esophagus - Muscularis
rs6065904 eQTL DNTTIP1 chr20_45906012_G_A_b38 2.1E-04 -0.12 Cells - Cultured fibroblasts
rs6065904 sQTL ZNF335 chr20_45906012_G_A_b38 3.3E-11 -0.65 Testis
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 1.3E-09 0.58 Heart - Left Ventricle
rs6065904 sQTL PLTP chr20_45906012_G_A_b38 4.5E-08 -0.32 Whole Blood
rs6065904 sQTL PLTP chr20_45906012_G_A_b38 4.8E-08 0.53 Spleen
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 1.3E-07 0.42 Esophagus - Mucosa
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 2.6E-07 0.49 Heart - Atrial Appendage
rs6065904 sQTL CTSA chr20_45906012_G_A_b38 1.0E-06 -0.41 Artery - Aorta
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 1.2E-06 0.33 Nerve - Tibial
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 1.2E-06 0.67 Brain - Spinal cord (cervical c-1)
rs6065904 sQTL TNNC2 chr20_45906012_G_A_b38 2.1E-06 0.54 Brain - Cerebellum
rs6065904 sQTL ACOT8 chr20_45906012_G_A_b38 2.1E-06 0.54 Brain - Cerebellum
rs6065904 sQTL WFDC3 chr20_45906012_G_A_b38 5.5E-06 0.23 Skin - Sun Exposed (Lower leg)
rs6065904 sQTL WFDC3 chr20_45906012_G_A_b38 9.4E-06 -0.28 Skin - Not Sun Exposed (Suprapubic)
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